Vol. 1. 1635. December 1995 Clinical Cancer Research 1635

Annual MeetingThe AACR’s Annual Meeting is one of the larg-

est and most important annual gatherings of sci-

enlists engaged in cancer research worldwide.

The next Annual Meeting will take place in

Washington. D. C., from April 20-24. 1996. The

Chairperson ofthe Annual Meeting is Lorraine J.

Gudas of the Cornell University Medical Col-

lege. Dr. Gudas and hen Program Committee will

invite outstanding scientists in the field to orga-

nize plenary sessions. symposia. methods work-shops. controversy sessions, and meet-the-expert

sunrise sessions. The Committee is currently ne-

viewing proffered papers for scheduling in mini-

symposia, poster discussion sessions. and pster

sessions. The deadline for abstract submissions

was December 1. 1995.

Gertrude Elion CancerResearch AwardApplications for the AACR’s 1996 GertrudeElion Cancer Research Award, supported by an

educational grant from Glaxo Wellcome Oncol-

ogy. are due February 15, 1996. The one-year.

$30,000 grant to a nontenuned Assistant Profes-

son supports meritorious basic. clinical, or trans-

lational research in cancer causation, prevention.

on treatment. Tenured faculty in academia. gov-

emment employees. and employees of private

industry are not eligible for this award. Informa-

lion and application forms were mailed to AACR

members and those who have requested applica-

lions. Nonmembens should request information

and applications from the AACR office.

New Research Fellowships AvailableThis year the AACR will offer two new one-

year, $30,000 grants to clinical or postdoctoral

fellows. A research award for a postdoctoral!

clinical felbo�s in clinical/translational research

will be sponsored by Amgen. A research award

for postdoctoral fellows in basic research willalso be available. To be eligible for either fel-

lowship. candidates must have completed the

M.D., Ph.D., on other doctoral degree. Candi-

dates must currently be a postdoctoral or clinical

research fellow and must have been a fellow for

at least two years but not more than five years

prior to the year of the award. All AACR mem-

hens will receive information and an application

form by mail in the near future. Nonmembens

may request information and forms from the

AACR office. The deadline for applications forthe new research fellowships is February 15. 1996.

Travel Grants from theComprehensive MinorityBiomedical Program of theNational Cancer InstituteFunds are being provided through the Compre-

hensive Minority Biomedical Program ofthe Na-

tional Cancer Institute for the travel of a limited

number of minority students to the 1996 AACR

Annual Meeting. Eligible scientists are young.

full-time pnedoctoral students, postdoctoral fel-

lows. and physicians in training who are engaged

AACRThe American Association for Cancer Re-

search (AACR) was founded in 1907 to bring

together active investigators of the cancer

problem for the presentation and discussion of

new findings and to foster advances in cancer

research. Today the Association has more than

10,000 members working in all of the subdis-

ciplines of cancer research in the United

States, Canada. and more than 50 other coun-

tries. Information on AACR programs and ac-

tivities can be obtained froni

American Association forCancer Research

Public Ledger Building150 South Independence Mall West

Suite 816Philadelphia, PA 19106-3483

Phone: (215) 440-9300

Fax: (215) 440-9313

The AACR welcomes applications for mem-

bership from the readership. Scientists en-

gaged in all areas of cancer research are eligi-

ble for membership. There are three categories

of membership: attire membership, open to

cancer researchers working in the Americas;

corresponding membership. to those working

outside the Americas: and associate member-

ship. to graduate and medical students, post-

doctoral fellows. and physicians-in-training.

Further information on the qualifications for

each category as well as the benefits of mem-

hership can be found on the application forms

at the back of this issue.

in cancer research or who have training that

could lead to contributions in this field.

This travel award program applies only to

minority groups that have been defined by the

National Cancer Institute as being traditionally

undernepresented in cancer research; these

groups are American Indians, Blacks, Hispanics.

Native Alaskans. and Native Pacific Islanders.

Only citizens of the United States and Canada or

scientists who are permanent residents in those

countries may receive one of these awards.

Although preference will be shown to au-

thors of abstracts that have been accepted for

presentation at the Annual Meeting. this is not

a requirement for the award. Awardees will be

selected on the basis of their qualifications. ref-

erences from mentors, and an estimation of the

potential professional benefit to the awardees.

An advisory committee consisting of members

of the AACR will review submitted applications

and letters of reference. The award will consist of

partial support of registration, travel, and subsis-

tence expenses incurred in connection with at-

tendance at the Annual Meeting.

Applicants will be chosen from minority insti-

tutions as well as the larger bodies of universi-

ties, colleges, and research institutes. Travel

grants are awarded to the applicant’s institution

to permit a minimum of three days of attendance

at the Annual Meeting. If accepted. applicants

will be expected to participate in any planned

activities for the awardees. They are required to

submit a brief report commenting on the scien-

tific sessions they attended at the Annual Meet-

ing and the minority travel program.

Further information and application forms

are available from the AACR office. Letters of

reference should accompany the application.The deadline for receipt of applications will beJanuary 26, 1996. Grants from this program

are also available for attendance at AACR

Special Conferences taking place in North

America. The brochure for each meeting con-

tains all necessary information.

AACR Special Conferences inCancer ResearchA number of meetings are now being orga-nized in the AACR’s new series of smaller

scientific meetings. Following are the topics.

dates, locations, and program committees for

some of these meetings. When full details of

each meeting are available, AACR members

will be the first to receive complete brochures

and application forms for participation in these

important conferences. Nonmembers may ne-

ceive this information by sending their names

and addresses to Meetings Mailing List, Ameri-

can Association for Cancer Research, PublicLedger Building, 150 South Independence MallWest, Suite 816, Philadelphia. PA 19106-3483.

Telephone: (215) ‘140-9300. FAX: (215) 440-

93 13. E-Mail: aacr@aol.com.

February 19-25, 1996

Cancer Susceptibility Genes and Molecular

Carcinogenesis

Chairpersons:

ALLAN BALMAIN. Glasgow. ScotlandCURTIS C. HARRIS. Bethesda. MDKENNETH OLDEN, Researc’h Triangle Park. NC

Keystone Resort. Keystone. CO

Marc/I 1-5, 1996

Proteases and Protease Inhibitors

Chairpersons:LYNN M. MATRISIAN, Nashville. TN

BONNIE F. SLOANE. Detroit. Ml

Marriott’s Bay Point Resort. Panama CityBeach. FL

June 8-/2, 1996

Inducible Genomic Responses

Chairpersons:WILLIAM T. BECK, Memphis. TN

JOHN A. HICKMAN, Birmingham. EnglandRICHARD I. MORIMOTO, Evanston, IL

Skamania Lodge. Stevenson (Columbia River

Gorge). WA

October 2-6, 1996

Novel Approaches in Blood and Marrow

Transplantation

Second Annual Meeting of the American

Society for Blood and Marrow Transplantation

Chairpersons:

0. MICHAEL COLVIN. Durham. NCBRUCE R. BLAZAR, Minneapolis, MNHotel Del Coronado. San Diego. CA

Vol. 1, 1637-1639, December 1995 Clinical Cancer Research 1637

‘May 1. 1994 through October 1 , 1995.

Acknowledgment to Reviewers

The Editor-in-Chief. the Associate Editors, and the Editorial Advisory Board wish to acknowledge with sincere appreciation the assistance of

the many reviewers who have generously contributed their time and efforts during the past yeani in the appraisal of manuscripts submitted to

Clinical Cancer Research. These reviewers not only have been of inestimable help in assessing the merit of original articles but also. by their

careful analysis and critique and their general and specific constructive recommendations, have often greatly enhanced the value of these

manuscripts. The quality of the journal can be attributed in large measure to the quality of their effort. We are sincerely grateful.

A

Gregory Adams

Peter Adamson

Jaffen Ajani

Mark Albentini

Anthony Albino

Maher AlbitarFrancis Ali-Osman

Michael C. Alley

D. Craig Allred

Paul Anderson

W. French Anderson

Michael Andreeff

Joseph Antin

Robert Arceci

Ralph ArlinghausDeborah ArmstrongDonald Armstrong

Bradley Annick

G. Arroyo

Carlos Arteaga

Larry Anthaud

Michael Atkins

Andrew Averbach

B

Dean BajoninD. BanenjeeShanyn Baker

Arthur BankMenashe Ban-Eli

Jos#{233}Baselga

Ashis Basu

Stephen B. Baylin

Scott Bearman

Juergen Becker

Atub Bedi

Thomas Behr

J. BeijnenWilliam P. Bennett

Jeffrey L. Benovic

Andrew Berchuck

David Bend

Jonathan Berek

Nathan Bergen

J. Berlin

Scott I. Berman

Irwin Bernstein

Steven H. Bernstein

J. Besterman

Kapil Bhabla

Michael Biner

W. Blanner

R. M. Blaese

Ronald Blasbeng

R. Chris Bleackley

Brent Blumenstein

M. Bocchia

Matthew Bocnte

Arthur Bogden

David Boldt

Bruce Boman

Michael Bookman

Ernest Borden

Epic Boven

Michael R. Boyd

Joseph Brennan

Murray Brennan

Dean Brenner

Thomas Brent

Garrett Brodeur

Carol BrownH. Broxtenman

N. Bnuchovsky

C. D. Bucana

Joan Bull

Howard Burt-is

Stephen Byers

C

Paul Cairns

Mitchell Cairo

Bruce CamittaStephen Cannistra

Robert CapizziGiovanni Capranico

David Carbone

Philip Canon

Canlos CarrenaWilliam Carson

Ephraim Casper

Melvin Center

Bruce ChabnerRaju Chaganti

Helen ChanKai Chang

Sunil Chattenjee

Martin Cheeven

Irwin Chen

Nai-Kong Cheung

Christopher Chitambar

Kathleen Cho

Randolph Christen

T. ChungI. Frank Ciernik

Gerald Clamon

John ClankRobert Clarke

James Cleary

Alfred Cohen

Amos Cohen

Susan Cohn

Steven Collins

Barbara Conley

Claudio Conti

Fran CookCarlos Cordon-Cardo

Jos#{233}Costa

Marion Couch

Kenneth Cowan

Craig Cropp

Ronald Crystal

Kevin Culben

Kenneth Culver

D

Steven D’Ambrosio

Peter Danenberg

D. Danielpour

Mary Danks

Zbigniew Darzynkiewicz

Nancy Davidson

Thomas Davis

Jerome Dc Cosse

Marc Dellian

Elaine Derbyshire

Eugene Dc Sombre

E. de Vnies

Daniel Dexter

Robert DiasioRobert Dickson

Robert Dillman

C. Divgi

Ethan Dmitrovsky

Bruce Dolnide

James Doroshow

N. C. Dracopoli

Anatoly Dnitschilo

C. Dumontet

Bo DupontPaul DurayHarold Dvorak

E

Janet EanyAlan Eastman

J. Eckardt

Gail Eckhardt

H. EhyaJanine Einspahr

W. El-Deiny

Laurence Elias

Richard Elledge

Lee Ellis

A. El-Naggar

Barbara EnsmingerBarbara Ensoli

Gary ErdmannLeonard Erickson

C. Erlichman

Elihu Estey

W. E. Evans

F

Thomas FaheyDominic Fan

Zhen FanDavid Farqumar

Hassan Fatallah-Shaykh

E. Feigal

David Fennebly

Robert Fenton

Soldano FerroneJorge Filmus

Howard Fine

James Finke

Jonathan Finbay

Richard Fisher

Kathleen FlandersJ. Fleming

Tito Fojo

Judah FolkmanKwun Fong

Kenneth Foon

Richard Ford

Arthur FrankelArnold Freedman

Eileen FriedmanMinoru Fukuda

Leo Furcht

G

Janice Gabrilove

Varsha Gandhi

Bernd GansbacherHaninder GarewalAdi GazdarClementina Geiser

Edward Paul Gelmann

1638 Acknowledgment to Reviewers

Stephen George D. Hochhauser Lawrence Leichman James Lee MurrayEugene Gerner David Hockenbeng W. R. Leopold V. MurtyGiuseppe Giaccone Robert Hoffman John Lettenio Ruth Muschel

Stephen Gillies Susan Flamm Honig Victor LevinD. Gary Gilliland Gabriel Hortobagyi Arnold J. Levine N

L. M. Glode Kathryn Horwitz Barry LevinsonPeter Goedegebuure Alan Houghton Brian Leyband-Jones David Nanus

Alec Goldenberg Peter Houghton Ti Lin Kathryn Nason-BurchenabDavid Goldenberg Lou Houston Charles Link Mark Nelson

G. J. Goldenberg Clifford Hudis Ibona Linnoila Robert Newman

Lori Goldstein Mien-Chic Hung Scott Lippman G�.rth NicolsonJared Golbob Kim Huston Alan List Stephen Nimen

Gary Goodman Nancy Hynes Philip Livingston Pe� Nisen

M. Gordon Albert LoBuglioMarshall Goren I Janina Longtine

Michael Gottesman G. Lopez-BeresteinJennifer Grandis Claudine Isaacs M. Scott Lucia J O’Brien

Stefan Grant William Isaacs Ruth Lupu M. J. O’Connell

Stephen Graziano Lyonel Israebs Lucio Luzzatto Peter O’ConnellWilliam Greco Henry Lynch Patrick O’Connor

Joel Greenberger j Herbert Oettgen

Geoffrey GreeneJean Grem M Edward H. OldfieldAnn Jakubowski David OlsonElizabeth Grimm

C. David James James OlsonT. M. Grogan John Janik Mack Mabry

Richard Grolia E. Gregory MacEwen boost OppenheimJin Jen John Ortaldo

Michael Grossbard Frank MaleyScott B. Jennings Sanford Markowitz Joyce O’ShaughnessyH. Barton Grossman Suresh Jhanwar Thomas O’SheaEric Groves John Marsh

Robert JilkaWilliam Gullick Daniel Martin

Bruce Johnson pPeter Maslak __________Michael Johnson

Joan MassagueH Joseph Jurcic Eric Masson David L. Page

Lynn Matrisian Lee PaiKJohn D. Hainsworth _________ Dana Matthews Larry Panasci

Sen-itinoh Hakomoni Ursula Matulonis G. Parmiani

D. Hallahan D. Kadmon Helena Mauceni Sybill PatanAnne Hamburger Greg Kalemkenian Amitabha Mazunnder Richard PazdurThomas Hamilton Robert J. Kaner John McBain Anthony Pegg

Ulrich Hammenling Philip Kantoff 1’. .1. McDonnell Roman Perez-Soler

Kenneth Hande Arlene Kantor David McLaughlin Manuel PeruchoJacquelyn Hank Bela Kanyicska Joseph McPhillips G. PetersYusuf Hannun Michael Kastan Paul Meltzer William PetersDan Haraf Michael Kelley S. Meltzer David Pfister

Susan Harlap Nancy Kemeny Adrian Menlo Lawrence PiroCurtis Harris Michael John Kennedy Neal Meropol Giuseppe Pizzorno

Mitsuru Hashida Kenneth Kinzler Roland Mertelsmann Leonidas C. Platanias

Ernest Hawk Michael Klagsbrun Frederick Meyers Alan Pollack

M. J. Hawkins David Kleiner Paul Meyers Yves G. PommierJohn Healey Eugenic Kleinerman R. Meyn Milan Potmesil

M. H. Heinemann D. Klimstra Mary Beth Mientin Philip PotterWilliam Held Wayne Koch James Mien William C. Powell

Ingegerd Hellstrdm Steven Koester Steven Miles Garth PowisMary J. C. Hendrix William Kopp Antonius A. Miller Elizabeth Poynor

Dorothee Herlyn Jason Koutcher Langdon Miller Janet PriceTerence Herman Mark Knis Bruce Minsky Hans Prochaska

Harry W. Herr Susan Krown Malcolm S. Mitchell

Peter A. Herrlich J. Krueger Malcolm Moore R

Charles Hesdorffer F. P. Kuhajda Briggs MorrisonPaul J. Hesketh Rakesh Kumar Jeffrey Moscow Robert RadinskyAllan Hess Robert Motzen William J. RamseyWarren Heston L Franco Muggia R. Beverly Raney

Gilda Hillman J. J. Mule J. Sambasiva RaoJoy Hirsch Paul Lange David Munn George RaptisWalter Hittelman Richard Larson John R. Murphy Frank J. Rauscher III

Clinical Cancer Research 1639

Peter Ravdin Gary Schwartz T WRichard Reba Kathleen Scotto

Many Relling Paul Seligman Raymond TactIc Scott Wadlen

Victor Reuter Peter Senter Chanis Takimoto John Wagner

Leonard Reyno Charles Shapiro Paul Talalay Raymond Warrell

Jerome Richie Fred Shapiro Moshe Talpaz Mania Webb

Victoria Rtchon Patricia Shaw Kenneth Tanabe Barbara Weber

James Rigas Jerry Shay Beverly Teicher Donna Weber

Charles Riggs Thomas C. Shea Margaret Tempero Jeffrey Weber

Cheryl Ritenbaugh Darryl Shibata C. Tenhorst Steven Weitman

Mark Ritter Dong Shin Kenneth Tew Sydney Welt

Ze’ev Ronat Carol Thiele L. R. WhitfieldRobert ShoemakerNeal Rosen Erik Thompson Mark Wick

David ShukenPaul Peter Rosen John Thompson Larry Wiesenthal

M. SicilianoMichael Rosenblum Donald Tindall George Wilding

Benjamin SikicD. Ross

Robert Silber Giampaolo Tortora Stephanie WilliamsBruce Roth Giongio Tninchieri Mark Willingham

David SilbersteinMace Rothenheng Glenwood Tnivers Cheryl Willman

Jack SingerJ. Michael Ruppert Donald Trump James K. V. Willson

Frank SirotnakJos#{233}Russo Wyndham Wilson

Mark SliwkowskiYoucef Rustum Robert WiltroutJohn W. Smith U Walter Wolf

S Mark Smulson Peter WorlandA. Sobrero Fatih Uckun

Robert Soiffer Susan UrbaMichel Sadelain _________Kenneth SomersHelene SageRemeo Spanjaard V James YangSydney Salmon _________

Leonard Saltz Thomas Spector Douglas Yec

Grady Saunders James L. Speyer Saroj Vadhan Richard Youle

David T. Scadden Walter Stadler George Vande Woude Charles Young

David Scheinbeng Peter Steck Anjit Vanki

R. Scheper Patricia Steeg Martina Veigl ZJoan Schiller Manyalice Stetler-Stevenson Jean Viallet

John Schindler W. Stetler-Stevenson T. Visakorpi A. Zauber

Jeffrey Schlom Gabniella Stozzi Ellen S. Vitetta Andrew Zelenetz

Stuart Schnitt Paul Sugarbaker Nicholas Vogelzang Bruce R. Zetter

Fniednich Schuening Sara Sukuman Everett Vokes Jesper Zeuthen

G. Schuunhuis Mario Sznol Stephan Voss Hanald zun Hausen

Vol. 1. 1641-1645, December 1995 Clinical Cancer Research 1641

AUTHOR INDEX

Volume 1

A

Abe, 0.. 1537

Adzick. N. S.. 327

Aeppli. D.. 913

Aguzzi. A., 207

Aherne, G. W., 391

Aksentijevich, I., 447Alberti. D., 493

Albertini, M., 481

Allard, P., 1 195

Allay, E.. 519

Allison, R. S. H., 129

AIlned, D. C., 1203

Alvarez, R. D., 1571

Alvond, W. G., 1327

Ambus, U.. 287Amid, A., 823

Amlot. P., 1623

Amos,C.J., 1617Andersen. J. A.. 881

Anderson. P. S.. 313

Andreeff, M., 583

Andrulis, I. L.. 907, 161 1

Anna, C. H.. 687

Anzai, H., 1095

Aplan. P. D.. 459Archer, G. E., 1545

Argenta. P. A.. 327

Aschele, C., 955, 1337

Assikis, V. J., 467

Athanasiadis, I.. 973

Atwood, A.. 847

August. D. A.. 351

B

Baak, J. P. A.. 81Bagnato. A.. 1059

Bahn, H., 775

Bailey. N.. 1275

Baker, L. H., 831. 1487Baker, M. A.. 935Baker, T. M.. I 133

Baldo, C., 1337Ball, E. D., 425, 607, 965. 1319

Balmanno, K., 1275

Banenjee. S.. 1421

Barbareschi, M., 189

Barbhaiya. R. H.. 105Baron, J-C., 1385

Barrett, J. C., 687

Bartel, S.. 269Bartemes, K.. 805

Baselga. J.. 161

Basser, R. L., 715

Bates, S. E.. 1581Batra, S. K., 859Bauer, J. J.. 1295Bayer. R.. 1495Bechhofer. R.. 481

Bedi, G.. 257

Beers, T., I 285

Begley. C. G.. 715

Beilstein, P., 813

Bellamy, W. T., 1563

Bello, D.. 1089

Benhar, I., 1023Bennett-Baker. P.. 539Benson, A. B.. Ill. 1 133

Berezin. F. K., I 133

Bergen. J. S.. 223

Bergen. N. A.. 223. 369

Bergeron. R. J.. 847

Berges. R. R.. 473

Berkowitz, I.. 699

Berman, S., 621

Bernacki. R. J., 847

Bernard, P.. 1 195

Bernstein. Z.. I 285

Berry, D., 699

Bertino, J. R., 631. 955

Bertoglio. S.. 955

Bevilacqua. P.. 189. l375

Bhalla, K., 559, 1399

Bharti, A., 269Bhatachanya-Chattenjee, M., I 285

Bhatia. U., 873

Bianco, A. R., 49, 161, 377

Bianco, C.. 49. 161, 377

Bi#{232}che.I.. 123

Bielenberg. D.. 19

Biggar, R. J.. 257

Bigner, D. D., 859, 1545

Bitnan, J. D., 185

Bittner. M.. I I

Bloom, E. J..607

Bloomfield. C. D.. 459

Blumberg. P. M.. 1581

Boddy, A. V., 1275, 1479

Bocnsma, T., 1301

Bolli, E. A.. 955

Bondy, M. L., 1617

Bonoldi, E., 1375

Boocock, C. A., 313

Bonacchi, P., 189, 1375

Borchert, A.. 481

Bosman, F. T.. 1301

Bottardi. S.. 147

Boudoulas. S., 797

Bova, G. S., 1471

Boyd, J.. 539

Boynton. J. D.. 1223

Breakefield, X. 0.. 1 171Breimer, D. D., 1525

Breitman, T. R., 637Brennan, E. J., 665

Brenner, D. E., 351

Brent. T. P., 1359

Bretti, S.. 147

Brooks, D.. 1259

Broussard, E. K., 1503

Brown, L. F., 1209Broxterman, H. J.. 81Bnuner, J. M.. 1617

Bnunner. N.. 1079

Bruno, S., 1337

Bnuynseels. J.. 287

Bruzzi, P.. 955

Bucana, C. D.. 19, 1095

Buchdunger. E., 813

Buchegger. F., 565

BOchler, M. W., 1413

Bullock, G.. 559. 1399

Burgaud. J-L., 1429

Burger. H., 1301

Burke. P. J., 295Burkert, W., 775

Burrows. F. J.. 1623

Busch, R., 199

Bussel, A.. 1463

Bussemakers. M. J. G., 1471

Buzdar, A.. 691

Byrd. D. R.. 1071

C

Cacace, A.. 113

Caffo, 0.. 189Caldarelli. D. D.. 527

Calvert. A. H.. 1275. 1479

Calvete. J. A.. 1275Calzone, K. A.. 539Camanda, M., 1495

Campion. M.. I 139

Cannistra. S. A.. 333

Cao. S.. 839Cap. B.. 791Capitelli. P.. 1503

Caraglia, M., 161

Cat-bone, D. P., 1 119

CarMichel. M.. 473Canon, P. C.. 63Carrasquillo. J. A.. 1447

Carver. J. P.. 935

Casey, G.. 1223

Catt. K. J.. 1059Cavalli. F.. 1517

Cebon, J.. 715

Chakraborty. M.. 1285Chamberlain, J., 539

Champ#{232}me, M-H., 123

Char, D. H., 41

Chastre, E., 147

Chatterjee. S.. 369Cheever, M. A., 1071

Chen, G. Z. J., 705Chen. J., 425. 1319Chen, L. B.. 621Chen. P.. 1557Chen. T.. 129Chen, W., 1071

Chenevent, T. L.. 643

Cheng. M-F., 223

Cheng. R.. 1447

Cheresh, P., 1209

Cheshire, P. J., 33

Chiang, L-C., I 13

Chinchilli. V. M.. 551

Chiocca. E. A.. I 171

Christensen, I. J.. 881

Chung. Y.. 1447

Church, J. M.. 1421

Ciardiello, F., 49, 161, 377

Ciernik, B. H. K., I 1 19

Ciernik, 1. F.. I I 19

Cisek, L.. 473

Clank, D. A., I 145

Clark, L., 965Clank, R. M., 287Claxton, D. F., 583, 1051Clendeninn. N.. 1275

Cockerell, C. J., I I 19Cohen. A. M., 899Cohen. B. B., 945Cohen. D., 545

Cole, K. A.. 797Coleman, N., 621

Coleman, R. E.. 921

Collins. C.. 1455

Collins, F. S., 539

Collins, J. M., 399

Collins, J. P.. 715

Collins, S. L., 95

Comoglio. P. M.. 147

Consoli. U.. 583

Coon, J. S., IV, 527

Cordner, L.. 1203Cordon-Cat-do. C., 545Costa, S., 1 125

Costanza, M. E.. 699Coto, E., 1043Cowan, K., 295Cowan, K. H.. 71, 129, 235, 889,

1447

Crawford, E. D., 57

Crebbin. V., 551

Creekmore, S. P., 1327Crown, J., 1267Crump. M., 287

Cunningham. J. E.. 1617

Cuniel, D. T.. 1571Curley, E. M., 551Curt,G., 1447

Curti, B. D.. 1327

Cussenot, 0., 1385

D

Daghighian. F., 1503

Dahlberg, W. K.. 785

Dahut, W., 1345Dalla Palma, P., 189Dalton, W. S., 1563Damiano, V.. 49. 161

Danielpour. D.. 129

Danishefsky, K.. 873

Dan#{248},K., 1079Darzynkiewicz, Z., 873

Davey, F. R., 459Davidson, B. L.. 651

Davies, S. L., 49

Davis, P. A., 797

Debernardis, D., 1337

Debinski, W., 1015. 1253

de Bree, R.. 277, 591Dc Coster, R., 287DeFranzo, B., 333

Dc Fusco, M., 1517Deisseroth, A. B., 583, 1051

deJong.J.. 1517

deMagalhaes-Silverman. M.. 607.965

1642 Author Index

Demura, H., 1537

Dengler, R., 199

den Hoblanden, W., 277, 591

Denicoff, A. M., 129

Dennis, J. W., 935

Derbyshire, E. J., 1623

Dettmar, P., 741Devereux, T. R., 687DeVictonia, C. L., 313

Dezube, B. J., 791Dhingra, K., 691

Di Castro, V., 1059Dickstein, B., 1581

di Isernia, G., 49, 161

D’Incalci, M., 1517

Di Renzo, M. F., 147

Disis, M. L., 1071

Divgi, C. R., 1503

Do, D. A., 1413

Dobberstein, K-U., 775

Dodge, R., 459Doglioni, C., 189

Dolan, M. E., 1133Donahoe, P. K., 343

Dong, B., 1421Dong, Z., 19Donnenbeng, A. D., 607

Dos Santos, B., 1259

Dotzlaw, H., 155

Dowsett, M., 1511Du,M., 169Dubielzig, R. R., 1 165, 1595

Duggan, D., 699

Dumenco, L. L., 519

DOt-st. M., 1125

E

Eastham, J. A., 1111

Eda, H., 1353

Edwards, C. C., 1359

Eekman, C. A., 81

Eger, G., 199

Eggermont, A. M. M., 1301

Einat, M., 823

El-Ashmawy, L., 763

Elbakri, H. R., 41

Elder, E. M., 607Elias, L., 615

Elledge, R. M., 1203

Ellis, L. M., 1095

Ellis, T. A., 805

Emmenich, B., 199Endo, M., 1353, 1537

Engin, K., 139

Epstein, J. I., I 1, 473

Estey, E., 169

Etienne, M. C., 991

F

Fabian, I., 823

Fan,D., 19Fang, X-J., 1223

Fanger, M. W., 425Favaro, D., 493Feller, N., 81

Feng, M., 1571

Fennelly, D., 575, 1267

Ferguson, J., 615

Ferrell, R. E., 763

Ferrone, S., 705

Feuerstein, I., 1447

Fidel, J., 1 165, 1595

Fidlen, I. J., 19, 1095

Fields, S. Z., 105

Figg, W. D., 797

Finn, R. D., 1503

Fischel, J. L., 991

Fisher, H. A. G., 57

Fisher, R. I., 805

Fisher, S. G., 805

Fisher, T. C., 391

Fittkau, M., 775

Flaherty, L., 1487

Hens, M. J., 1301

Foekens, J. A., 1079

Foon, K. A., 1285

Fordyce, W., 1447

Formento, P., 991

Foster, B. J., 831, 1487

Fournier, G., 1385

Fox, L. E., 1595Fox, R. M., 715

Ft-add, Y., 435, 1195

Fraley, E., 913

Frank, C., 839Frank, T. S., 539Frankel, A., 1223

Frankel, S. R., 459

Fraschini, G., 691

Fneschi, A., 493

Fniberg, S., 1189

Friedman, H. S., 1545

Friedman, K. D., 1 145

Friess, H., 1413

Fnigilbana, H., 41

Frye, D., 691

Fu, S., 583Fuchs, H. E., 1545Fujita. K., 501

Fuks, Z., 545

Fukutomi, T., 261

Fuqua, S. A. W., 155Funukawa, T., 305

Furuta, K., 417

G

Gabra, H., 945Galassi, A., 1375

Galligioni, E., 493

Gambacorti, C., 481

Gambel, A., 1051Gambino, A., 185

Gan, J., 481Gandhi, V., 169

Gantchev, L., 775

Ganzenko, N., 973Garay, E., 1463

Garber, J. E., 539Garcia, R., 731

Gaspanini, G., 189, 1375

Gaudette, D. C., 1223

Gazdar, A. F., I 1 19, 1623Gellerman, G., 823

Gentili, D., 1517

Geoffnoy, F., 1345

Get-son, S. L., 519

Gespach, C., 147

Gha.zvini, S., 41

Giacomini, A., 147

Giantonio, B. J., 57

Gill, P. G., 715

Gilmoun, S. K., 665

Giordano, S., 147

Givehchian, M., 1 125

Gleich, G. J., 805

Goeckeler, W., 1447

Goldberg, G. L., 313

Goldberg, M. R., 57

Goldspiel, B., 797

Goldstein, N. I., 1311

Goblin, S. M., 763

Gonzalez, M. V., 1043

Goodbody, A., 1223

Gordon, N., 441

Gore, S. D., 295Gonetzki, L., 741

Goss, P. E., 287, 935

Gottesman, M. M., 447

Gousse, A. E., 1 1 1 1

Gradishar, W. J., 973

Graeff, H., 741

Gratama, J. W., 1301

Gray, J. W., 1455

Green, M. D., 715Greenberg, R. E., 57Greenberg, S. J., 1285

Greenblatt, M. S., 615

Grem, J. L., 1345

Gniem, K., 527

Griffin, C., I 1

Grogan, T. M., 1563

Gr#{248}ndahl-Hansen, J., 1079

Gruss, P., 207

Guan, X-Y., I 1

Guarrasi, R., 377

Gudas, J. M., 71, 235, 889Guglielmi, A. P., 955, 1337

Guglielmi, R. B., 1375Guillem, J. G., 899

Gulec, S., 1503

Gupta, E., 1133

H

Hagen, K., 913

Haleem, A., 527

Halter, S., 351

Hamby, A., 215Hamilton, N., 1267

Hanania, E. G., 583

Hank, J. A., 481

Hansen, B., 881

Hat-pole, D. H., Jr., 659

Harrap, K. R., 391

Harris, A. L., 49, 189, 215

Harris, L. C., 1359

Harrison, M., 1267

Hart,J., 1103

Hartwell, L., 1067

Hartwick, R. W. J., 1611

Harvey, H. A., 551

Harvey, J. P., 551

Hanwood, F. G., 723

Hashimoto, H., 369

Hawkins, R. A., 921, 945, 1603

Hayes, D. F., 791

Hecht, T. T., I 259

Heckel, V., 179

Hedge,M.W., 1153

Hedlund, T. E., 997

Heilbnun. L. K., 1487

Heimbrook, D. C., 57

Helfand, S. C., I 165, 1595

Henderson, I. C., 699, 791

Herath, J., 1 1

Henndon, J. E., II, 659, 1545

Hersh, E., I 139

Herzig, R., 965

Henzog, C. E., 1391

Hess, K. R., 1617

Hickson, I. D., 49

Hietala, 0. A., 665

Higgins, T. J., 805

Hilsenbeck, S. G., 155, 1203

Hilton, S., 1503

Himpler, B. S., 105

Hines, J. D., 441

Hirai, S., 705

Hirohashi, S., 261

Hirst, G. L., 1603

Hittelman, W. N., 677

Ho,C., 621Hoffman, R. M., 305, 1537

Holli, K., 1455

Holub, B. J., 1223Holzhausen, H-J., 775

Hong, W. K., 677

Hon#{225}kov#{225},I., 359

Hortobagyi, G. N., 691

Hoshina, S., 961

Houghton, A., 1259

Houghton, J. A., 33, 723

Houghton, P. J., 1359

Hrycyna, C. A., 447

Huang, P., 1005

Huang. Y.. 559, 1399

Hudis, C., 1267

Huguet, E. L., 215

Huizenga. E.. 1563Hurd, D., 965

Hurteau, J., 1223

Hurwitz. S.. 269

Huseby. E. S., 1071

Hutchinson. J., 527

Ibrado, A. M., 559, 1399

Ichige, K.. 565

Ide, T., 1245

Igwemezie, L. N., 105

Ikarashi, H., 501

Ikenaga. M.. 769

Imai, H., 417

Imamuna, M., 769

Imazawa, T., I 031

Inada, K., 961. 1031

Isaacs, J. T., 473

Isaacs, W. B., 1471

Ishihara, A.. 1035

Ishitsuka, H., 1353

Ishizaki. K.. 769

Isola, J., 1455

J

Jackson, G. L., 179

Jackson, R. C., 1275

Jacob, J., 797

Jacobs, S., 1511

J#{228}nicke,F., 741

Clinical Cancer Research 1643

Janrard, D. F., 1471

Jenkins. R.. 1 1

Johnson, D. E., 473

Johnson, J. T.. 763

Johnston, A.. 1275

Johnston, S. R. D.. 151 1

Jones,A., 1511

Jones, J. G., 313

Jones, R. J.. 295

Joob. A., 973

Jordan. V. C., 467

Juliusson, G., 385

Jurcic, J. G., 1439

Juttner, C. A., 715

K

Kallioniemi, A.. 1455

Kallioniemi, 0-P., 1 1, 1455

Kalna, J., 699Kashman, Y., 823

Katayose, D., 71, 889

Katzenellenbogen. J. A., 921Kaul, S., 105Kaur,J., 1217Kavanagh. B. D.. 1557

Kawamura, E., 1537

Keating, M. J., 169

Kefer, C., 805

Keizer, H. J., 1525

Kelland, L. R., 981

Keller, E. T., 1595Kelsen. D., 1503

Kemeny. N., 1503

Khaled, Z., I 13, 509

Khan, T. M.. 509

Kies, M. S., 973

Kim, B., 643, 65 1

Kimura, K.. 1537

Kinch, L., 1495

King, R. J. B.. 1603

King, S. W., 1623

Kinsella, T. J..407

Kioussi, C., 207

Kisseberth, W. C., I 165

Kita. H., 805

Kitadai, Y., 1095

Kiyosawa. K., 417

Klein, R. C., 71, 235

Kleinerman, E. S., 1391Kleinerman, J., 441

Klijn, J. G. M., 1079Klumpen, E.. 81

Kobayashi. T.. 1051

Kobnin, M. S.. 1413

Kochen, 0.. 1209Kodama, S., 501

Kdhler, H., 1285

Kohn, E. C., 399, 797Kok,T., 1301Kondo, S., 961

Korc, M., 1413Kornblau, S. M., 1051

Kornfeld, S., I 259

Kotelnikov, V. M., 527

Kowbel, D., 1455

Kraut, M., 1487Krohn. K. A., 921

Knoll, S., 41

Kuan, C-T., 1589

Kubota, T., 305, 1537

Kufe, D., 269, 565

Kuipen, C. M.. 81

Kumar, R.. 551

Kuniyasu. H., 1245

Kunugi, K. A., 407

Kuo, D. Y. S.. 313Kunian, M. S., 343

Kunzman, I. D.. I 165, 1595

Kynitsis. A. P.. 1617

L

Lacroix, J., 1125

Lai, L. T., 63

Landberg, G., 417

Landreneau, R. J., 763

Langdon. S. P.. 945, 1603

Langer, C. J.. 105, 1407

Lankelma, J., 81

Laohavinij. S., 1479

Larsen, J. K., 881

Larson, R. A., 459

Larson, S. M., 921, 1503

LaRue, H., 435Latil, A., 1385

Lattman. J.. 41

Law, J. C., 763

LeBeau, M. M., 459

Lee,J.J., 1103Lee, S. W., 1209

Leeper, D. B., 139

Lejeune. S.. 215Leonard, R. C. F.. 945

Letarte. M., 1623

Letterio, J. J., 129

Levin. V. A., 1617

Levitt. D., I 139

Levy, N., 1503

Levy, S., 269

Li, W-W., 631Lianes, P., 545

Lidereau, R., 123, 1385

Liliemark, J., 385

Lin, P-S., 1557

Lin, R. Y., 327

Lind, M., 1275

Linden. H., 1259

Linehan, W. M.. 57

Liotta. L. A., 797

Lippman, S. M.. 677

Lipton, A., 551

Lishner, M.. 823

Listen, J., 607

Litam, P. P., 105

Little, J. B., 785

Litwin, S., 665, 1407

Liu, C.. 705

Liu,L.F.,417

Lock-Lim, S.. 1203

London, C. A., I 165

Longo. D. L.. 1327Ldnn,S., 1189Ldnn, U., 1189

Look, M. P.. 1079

L#{243}pez-Larrea, C., 1043

Lora, M. E.. 1503

Lorimer, I. A. J., 859LoRusso, P. M., 831, 1487

Lotan, R., 677Loutfi, S., 1495

Lubin, R., 1463

Ludden, L. K., 399

Luna, E.. 441

Lutterbaugh. J.. 441

Lydon. N. B.. 813

Lynch, C., 269

Lyss. A. P., 699

M

MacEwen, E. G., 1 165, 1595

Mackay. J., 945

Mackay. W.. 223, 441

MacLaughlin. D. T.. 343

Madewell, B. R., I 165, 1595

Maher. D. W.. 715

Malley, V., 965

Mammoliti, S., 955

Mangalik. A.. 615

Manganano, T. F.. 343

Manivel, J. C., 913

Manathi, U. K., 1359

Margolin. K. A., I 139

Markowitz. S., 441Marks, J. R., 659

Marsik, S.. 185

Martinelli. G., 1517

Marymont. M., 973

Matsubara, N.. 665

Matsumoto, T., 1353

Matthews, J. P.. 95

Mauch, P.. 621

Mauri, F. A., 189

McAleer, C., 105

McCahill, L., 1071

McCormick, C. I., 731

McCormick, J.. 1487

McGill, J., I I

McLendon, R. E., 1545

McLcod, D. G.. 1295McWatters, A., I 391

Mellors, A., 1223

Melsheimer, P.. 1 125

Meltzer, P., 1 1

Mendelsohn, J., I, 161, 545. 675.

921, 1311

Men#{233}ndez, M. J.. 1043

Merajven. S. D., 539

Messing. E., 57

Mett. H.. 813

Meyer. T.. 813

Michael, S. I.. 1571

Michelassi. F.. I 103

Mick, R., 1133

Miki. K.. 377

Milano, G., 991

Milenic, D. E.. 1447. 1503Miller, E. M., 407

Miller, G. J.. 997

Miller, M.. 973

Miller, W. R., 1603

Mills, G. B., 1223

Minna, J. D., I I 19

Minossay. L.. 147

Mittelman, A.. 705

Miyashita. T.. 559

Miyata, Y.. 599

Mizoguchi. H., 1327

Moffatt, K. A., 997

Mokotoff, M., 425

Moore, K., 481

Moore, M.. 1267

Moore. M. A. 5.. 3

Monelli. L.. 189

Moretti, C.. 1059

Mori. A. M., 955, 1337

Mori, K., 1353

Morton. C. L., 33Mostofi, K. F., 1295

Moul, J. W.. 1295

Mousses, S., 907

Mulder, G. J., 1525

Mulders, T. M. T., 1525

Muller. M., 813

Mulligan, T., 1447

MUnstermann, U., 199

Murphy, L. C.. 155

Musaba. E.. 257

Mwansa, N., 257

Mycroff. L.. 441

N

Nagler. A., 823

Nagura. H., 1537

Nakanomyo. H.. 599

Nakao, I.. 1537

Nawabi, A.. 1399

Nelson, H., 1071

Netto. G.. 545

Neuwelt, E. A.. 731

Newell, D. R.. 1275, 1479

Newman, R. A.. 691

Nguyen, H.. 71, 889

Nguyen, P., 913

Nie, H., 1421

Niehans, G. A.. 913

Niloff, J..333

Nilsson, B., 1189

Nishiwaki. Y.. 599

Noble-Topham. S. E.. 161 1

Noone, M. H.. 129

Nooter, K., 1301

Nordlinger. B.. 147

North, P., 49

Norton, L.. 1267

Novotn#{225}, H., 359

Nowak, B.. 169

0

Oberman. E. J.. 847

Obini, N. I.. 1253

Obradovich, J. E., I 165. 1595

O’Brien, J. M.. 41O’Brien, T. G.. 665

Ochoa, A. C., 1327

Odeleyc. A.. 1563O’Driscoll, K. R., I 13

O’Dwyer. P.. 105

Offord, K. P., 805Ogawa. N., 1537Ohtsu, T., 599

Oka, M., 235

Okuno. K., 1071

Oliff, A. I.. 57

Oliveno, M.. 147

Olopade. 0. 1.. 1133Olver, I., 715Oostrum, R., 1301

Op#{225}lka,P., 359

Oppelt. P.. 741Orr,R.M.,391

T

1644 Author Index

Osborne, C. K., 921

Oseroff, A. R., 1285O’Shaughnessy. J. A., 129, 1447

O’Shea, J. J., 1327Ossenkoppele, G. J., 81Ottensmeier, C., 333

Ottesen, G. L., 881Ouchi, K. F., 1353Ouwerkenk, J., 1525Ozcelik, H., 907

P

Pache, L., 741Packenham, J. P., 687Pagani, K., 1145

Pagani. 0., 1517

Pai, L. H., 129, 1545, 1589

Paik, C., 1447

Pak, A. S., 95Panje, W., 527Pantazis, P., 1235Pappot, H., 1079

Pastan, I. H., 57, 447, 859, 1015,

1023, 1253, 1545, 1589

Patel, R., I 13Peace, D. J., 1071, 1495Pearse, H. D., 731

Pello, M. F., 1043

Pepe, S., 49, 377

Perentesis, P., 1447

Percy, L.. 565Pcrez-Soler, R., 1369Pensichetti, J., 965

Peters, H. A., 1079

Petruzzelli, G. J., 95

Petrylak, D., I 13, 545

Pezzella, F., 189, 1375Pham, T. M., 539Piantadosi, S., 295Pieters, R., 81Pincus, S., 1285

Pincus, S. M., 607

Pinedo, H. M., 81Piscitelli, S. C., 797

Piwnica-Worms, D., 921Plebani, M., 147Plewan, A., 199Plunkett, W., 169, 1005

Pollard, J. W., 313Ponnathpun, V., 1399

Poplin, E., 1487Porte, H., 147

Porter, C. W., 847Poulsom, R., 215Powers. G. C., 1327

Powers, S. K., 1253Prasanna, P., 865Preisler, H. D., 527

Prewett, M., 1311Priebe, W., 1369Put-i, R. K., 1253

Qin, H.. 1071

Quaia, M.. 493Quak, J. J.. 277, 591

R

Rabiasz, G. J., 1603Rabkin, C. S., 257

Rad, N., 1495Rademaker, A., 973

Radinsky, R., 19

Rafi, I., 1275Rainov, N. G., 775

Ralhan, R., 1217Ranjit, G. B., 223

Rapp. L.. I 145Raptis. G., 1267

Ratain, M. J., 699, 1 133

Ray. S., 559. 1399Reba. R. C.. 921Reed, E., 797Reed, J. C.. 559, 1399Regenass, U.. 813

Regis, J., 1581

Reich, L., 1267Remsen, L. G., 731

Ren#{233}e,N., 991Resta, D., I 139Reuter, V., 545

Reynolds, J., 1447

Rhee,R.J., 1171Richards, W. G., 659

Rideout, D., 113Ridge, J. A., 1407Rinehart, J.. 1 139

Risebeng, D., 1447

Risin, S., 19

Robertson, L. E., 1005

Rockwell, P., 131 1Rodriguez, C. 0.. Jr., I 165, 1595

Rogers. P. M.. 981Rollandi, G. A., 955

R#{248}nne,E., 1079Roos, J. C., 277, 591

Rosenberg. M., I 165, 1595

Rosenfeld, M. E.. 1571

Rosenthal, R. C.. 1595Rosowsky, A., 269Ross, B. D., 643, 651Rosso, R., 955, 1337

Rotenberg, S., I 13Roubkov#{225},H., 359Rubin, E.. 269Rudi, A., 823Ruggieno, A., 161, 377

Runowicz, C. D., 313Russell, D., I 285

Russell, I., 715

Russo, P., 57, 1337Rustum, Y. M., 441. 839

Rybka. W. B.. 607

S

Saijo. N., 599

Sainz de Ia Cuesta, R., 343Saito, T., 1537

Sakakura, T., 1035Samid, D., 865Samuels, B. L., I 85

Santarosa, M., 493

Sarkis. A.. 545

Sarosdy.M.F.. 11.57Sarosy, G., 797Sasaki. Y., 599

Sasano, H.. 1537

Sasano, N.. 1537

Sausville, E. A., 637

Sauter. E. R.. 1407Scala, S., 1581

Scardino, P. T., 1 1 1 1

Schacter, L. P., 105

Scheinberg, D. A., 63, 1 179, 1439

Scheper, R. J., 1301Scher, H. I., 545Schilder, R. J., 105Schillen, J. H., 481

Schlichtholz, B., 1463Schlom, J., 1447, 1503

Schmidt-Ullrich, R. K., 1557

Schmitt, M.. 741

Schneider, A., I 125

Schneider, P., 813

Schuurhuis, G. J., 81

Scott, A. M., 1503

Seidman, A. D., 247

Self. S., 1399Selvaggi, K., 965

Seon. B. K.. 1285Senafinowski, P., 391

Sessa. C., 1517

Sesterhenn, I. A., 1295

Seth, P., 71, 889Seweryniak. K. E., 847

Sexton, G.. 731Shack, S., 865Shapiro. C. L., 699, 791

Shanma, A., 1223

Sharp, S. Y., 981

Shay, J. W., 1245

Shen, D. A., 459

Sheridan, W. P., 715Shibagaki. I., 769

Shimada, H.. 1071

Shimada, Y., 769

Shirasaka, T., 839

Shtern, F., 921Sidransky. D.. 257

Siegal, G. P., 1571

Siegel. B. A.. 921

Silfverswhrd, C., 1189

Silverman, R. H., 1421

Simoneau, M., 435

Sinicrope, F. A., 1 103

Skorecki, K. L., 161 1

Sladek, N. E., 1 153Slawin, K. M., I 1 1 1

Smith, H. 0.. 313Smith, I. E., 1511Smith, T., 691

Smyth. J. F.. 945, 1603

Snow, G. B.. 277, 591

Sobol, R. E.. 459

Sobreno, A. F., 955, 1337Soltis, M. J., 797

Sondel, P. M., 481

Sonneveld, P., 1301

Sorrentino, B. P., 1359

Sosman, J. A., 481, 805. 1495

Soussi, T.. 1463

Spada. A., 493Spector. T.. 991Spergel, D., 1059

Sporn. M. B., 129

Sreerama, L., 1 153Srivastava, D. K., 1359

Snivastava. S., 763, 889, 1295

Stanley, E. R., 313

Stapleton. A. M. F., 1111

Stapleton, G. E., 997Steel, C. M., 945Stein, C. A., 1 13, 509

Steinberg, S. M., 797

Stenkvist, B.. 1189

Stephens, L. C., 1369

Stetler-Stevenson, W., 899

Stewart. C. C., 459Stewart, C. F.. 33Stiff. P. J.. 1495

Stock, W., 459Storer, B., 481

Stoter, G.. 1301Strobl, S. L.. 1327

Strong. J. M.. 399Stuart, E. T., 207

Suhrez. C.. l()43Suganbaker, D. J., 659

Sugimoto. Y., 447

Sullivan, K. M.. 327

Sunkutu, R., 257Surmacz, E.. 1429Susaneck, S., I 165

Suzuki, H., 961

Szallasi, Z.. 1581

Szer,J., 715

TactIc, R., 1259

Tagliaferri, P., 161, 377

Tahaoglu, E.. I 285

Tahara. E., 1095, 1245Tahana. H.. 1245Takahashi, M., 1071

Takahashi. N.. 637Takahashi, T., 501

Takahashi, Y., 1095

Takakuwa, K., 501Takimoto, C. H.. 1345

Talbot, D. C.. 391

Tamaki, H.. 1035

Tamiya.T.. 1171

Tamura, S., 1353

Tamura, T., 599

Tan, E. M., 417

Tan, S.. 1495Tanaka, H.. 769Tanaka, K.. 501

Tanaka, Y., 1353

Taniguchi, T.. 1031

Tanner. M. M., 1455

Taverna, M.. 1337

Taylor. C.. 1259

Taylor, G. A., 1275, 1479

Taylor, J. A., 687Taylor. L.. 945

Taylor, S., IV, 527

Tazzani, P. L., 1623

Tecce, R., 1059

Teillaud, J. L., 1463

Testolin, A., 1375

T#{234}tu,B., 1 195

Theriault, R., 691Thompson. T. C.. 1 1 1 1

Thomssen, C.. 741

Thorpe, P. E.. 1623

Tiersten, A., 1267

Clinical Cancer Research 1645

Tillman. D. M., 723

Timme,T.L.. 1111

Tinazzi, A., 1517

Tirkkonen. M.. 1455

Tixi, L. M.. 955

To. L. B.. 715Tobe,S.W.. 1611

Toi, M.. 961, 1031

Tokita, H.. 1353

Tokunaga. A.. 501

Tominaga. T., 96 1 . 1031

Tong. W. P.. 631

Tonkinson, J. L., 509

Toppmeyer, D., 269

Torri,V., 1517

Tortora, G.. 49, 161, 377

Traganos. F., 873

Traxlen. P., 813

Trent, J.. I 1Tretyakov, 0., 791

Tninks, U., 813

Triozzi, P., 1139

Tnites, D.. 269

Trunct,P.. 15l1

Tsuda, H.. 261

Tupchong. L.. 139

Tyc, L. M.. 287

U

Uhlman, D. L., 913

Urba, W. J., 1327

V

Vachtenheim, J.. 359

Vahdat, L., 1267

Vaickus, L., I 285

Vail, D. M.. I 165. 1595

Valdivieso, M.. 1487

Valenti, M.. 1337

Van Den Berg. C.. 1 1

van den Velde, E. A.. 1525

van Dongen. G. A. M. S.. 277,

591

van Heijningen, T. H. M.. 81

Vanin, E. F., 1359

van Lingen. A.. 277

van Putten, W. L. J.. 1079

van Wingerden. K. E.. 1301

Vasavada, S., 1421

Veltni, R. W.. 473

Verdenio, P., 189, 1375

Vernon, S. W., 179

Visakorpi, T., I I

Vitantonio, K.. 519

Vitetta, E. S., 1623

Vogel, C. A., 565

Von Hoff, D., I 1

Von Knebel Doebenitz, M., 1 125

Vukanovic, J., 473

w

Wadden, N. A., 287

Wagata, T., 769

Waghnay. A.. 747. 755. 1089

Wakefield, L. M.. 129

Walde, D.. 287

Walsh, P. C., 473

Walters, R., 691

Walther, M., 57

Waneck, G. L., 343

Wang, L., 1421

Warnen,E., 1611

Waterman, F. M.. 139

Watson, J. E. V., 945

Watts, P., 665

Webber, M. M., 747. 755, 1089

Webber, S.. 1275

Weben, B. L.. 539Wedge. S. R.. 1479

Wei,M.X., 1171Weinstein, R. S.. 1563

Weissfeld, J.. 763

Weizel, H. A. E.. 287

Welch, M. J.. 921

Weng. L-J., 295

Wesly. 0. H.. 481

Westbrook, C. A.. 459

Westerman, A. M.. 1301

Wheeler, T. M.. I I I I

Whitacre, C. M., 223

White, C. M., 687

White, L.. 185

Whitehead, R. P.. 1 145

Whiteside, T. L., 607, 763

Wiegand, R. A.. 831

Wikstrand, C. J.. 859

Wild, C. P., 1463

Wilhelm, A. J.. 277

Williams, B. R. G.. 1421

Williams, J. M.. 1503

Wilson, V. L.. 865

Wirz, B., 813

Wittens, L. M., 551

Woennen, S. M.. I 125

Wong. G. Y.. 705

Wong. J. R.. 621

Wood, V., 269

Wright, J., 105, 791

Wright. M. A.. 95

Wright, S., 1005

Wu, K., 699Wurster-Hill, D., 459

Xu, J., 539

x

Xu.Y., 1179, 1223

V

Yamaguchi. K., 1353

Yamamoto, Y., 1031

Yamanaka, Y., 1413

Yang,G.. 1111Yao, T-J., 1267

Yarkoni, S., 823

Yasui, W., 1245

Yasutomi, M., 1071

Yokozaki, H., 1245

Yoshida, T., 1035

Young. C.. 1503

Young. M. R. I., 95

Yum, K. Y.. 665Yung. W. K. A., 1617

z

Zaman, G. J. R.. 1301Zea. A. H.. 1327

Zeng. Z-S., 899

Zhang. G., 913Zhang, W., 1051Zhang. Z-F.. 899Zhou, A., 1421

Zhou, J-H., 425, 1319

Zhu, D., 1617

Zilcha, M., 295

ZOller, M., 1125

Zou, Y.. 1369Zu, Z.. 583

Zucchetti, M., 1517

Zuklys. K., 1311

Zwelling. L. A.. 1391

Vol. 1. 1647-1661, December 1995 Clinical Cancer Research 1647

SUBJECT INDEX

Volume 1

A

Acquired immunodeficiency syndrome: see

AIDSActivating factor

ovarian cancer. characterization. I 223

ada

therapy. munine bone marrow. 1359

Adenocarcinomaadvanced

‘77Lu-Iabeled CC49, phase I study. 1447

Adenocarcinoma, colonFUra-leucovonin activity. xenografts. 33

Adenocarcinoma, endometrialetiopathogenesis

colony-stimulating factor I and. 3 13

Adenocarcinoma, lungN’,N’ -diethylnonspermine efficacy

against. preclinical. 847

e,l�B-2 and p53 oncogene expression. 659

Adenovirusexpressing p53

cytotoxic effects. mammary epithelial

cells. 889

-mediated transfer

herpes simplex virus thymidine kinase

gene. experimental intracranial

gliomas. 651

Adoptive immunotherapystem cell transplantation and. immediate

posttransplant. 607

tumor-infiltrating lymphocytes. advanced

epithelial ovarian cancer, 501

Aerodigestive cancerretinoid chenioprevention. basic research

to clinics. 677

AG337pharmacokinetics and pharmacodynamics.

24-hour study. I 275

AIDS-related Kaposi’s sarcoma

clonality. 257

TGF-f3 and TGF-�3 receptors expression.

I I 19

Aldehyde dehydrogenaseclass 3

salivary, induction, I 153

Alkylatorsrapidly cycled high-dose. metastatic breast

cancer. I 267

0 6-Alkylguanine-DNA alkyltransferaseactivity. human colon cancer, 519

Alkyltransferasegene expression. mtinine bone marrow.

I 359

9-Aminocamptothecin

effects on nascent bone marrow DNA.

I 345

phase 1 and pharmacokinetic study. 269

5’-Aminothymidinemodulation of iododeoxyunidine

radiosensitization, human colon

cancer cells. 407

Amonafideadvanced breast cancer, Cancer and

Leukemia Group B study. 699

Annamycinliposomal. preclinical toxicity. 1369

Antibody: see also Monoclonal antibodyanti-idiotype

T-celI lymphoma therapy. immune

responses. I 285

antitransfernin receptor. 42/6

phase Ia trial, 1259

bispecific 251 x 22 (anti-CD33 X anti-

CD64)

acute myeloid leukemia cell lysis, 1319

chimenic

anti-EGFR (C225). biological efficacy.

human tumor xenograft model, 131 1

p53 protein. various cancer types. 1463

ras proteins, colon cancer, 1071

-specific mode, human endothelial cells

immunotoxin-mediated vascular leak

syndrome. I 589

Anticancer agentscarbohydrate processing inhibitors, 935

Antifolateantipunine

lometrexol, with oral f�lic acid

supplement. phanmacokinetics. 1479

thyniidylate inhibitors

AG337. 24-hour study. I 275

antitumor effects. human soft tissue

sarcoma cell lines. 631

Antigenhigh molecular weight-melanoma

associated

mimicry by mouse anti-idiotypic mAb

MK2-23, malignant melanoma. 705

highly restricted T-cell

anti-idiotype antibody mimicking. T-cell

lymphoma therapy. I 285

prostate-specific

human prostate cancer cell invasion

facilitation. �089

tumor-associated

prognostic factors. transitional cell

bladder carcinoma. 1 195

Anti-idiotype therapyT-ceIl lymphoma. immune responses. 1285

Antileukemic drugsnovel

norsegolinc and dibezine, 823

Antineoplastic agentssuramin

cellular pharmacology. 509

Antipurine antifolatelometrexol. with oral folic acid supplement

phanmacokinetics. 1479

Antitransferrin receptor antibody 42/6phase Ia trial. 1259

a 1-Antitrypsinproteolyzed

urinary excretion, acute myeloid

leukemia. 199

Apoptosiscell cycle control. nitrogen mustard, 873

drug-induced

c-jun induction and. human acute

leukemia cells. 559

high molecular weight DNA

fragmentation. leukemia cells. 1005

growth factor-induced

prevention by PMLIRARU. acute

pnomyelocytic leukemia. 583

taxol-induced

protein kinase modulators and. human

leukemic cells, I 399

1 -�1-D-Arabinofuranosylcytosinesensitivity, acute myeloid leukemia, 81

Aromataseletrozole inhibition, postmenopausal breast

cancer patients. I 5 1 1vonozole inhibitor

advanced breast cancer therapy. phase II

study. 287

Ascites

ovarian cancer

ovarian cancer activating factor,

characterization. I 223

AstrocytomasPAX5 expression. 207

Ataxia telangiecta.siahetenozygote response to fractionated

radiation, 785

Autoantibodiesanti-DNA topoisomerase II. liver cancer,

417

p53. glioma. 775

Autologous peripheral blood stem cellstransplantation and immunotherapy.

immediate posttransplant. 607

5-Aza-2’-deoxycytidine-induced carcinogenesis

phenylacetate suppression. 865

B

Bacterial alkyltransferasegene expression. munine bone niarrow.

I 359

bcl-2expression

and node-positive breast cancer

outcome, 189

prognostic value, stage II colon

carcinoma, I103

VP-16-resistant cells. 1391

Bl(dsFv)PE38immunotoxin characterization. human

carcinoma xenognafts. nude mice,1023

bFGF: see Fibroblast growth factor, basicBl(Fv)PE38

immunotoxin characterization, human

carcinoma xenografts in nude mice.

1023

Bis-acetato-ammine-dichlorocyclo-hexylamine platinum(IV)

transport. ovarian carcinoma cell lines. 981

4,5-Bis(4-fluoroanilino)phthalimideEGF-R kinase inhibitor, in I’iv() antitumor

effects, 813

Bladder carcinomac-erh- B2 amplification. prognostic value,

I 189

1648 Subject Index

MRP expression, 1301superficial

oncotoxin TP4O, phase I clinical study.57

transitional cellhuman papillomavirus, 435tumor-associated antigens, prognostic

factors, 1 195

Blood: see Peripheral bloodBlood.brain barrier

osmotic disruption

irradiation and chemotherapy, rodent

model, 731B3-LysPE38

dosage effect on survival, carcinomatousmeningitis rat model. 1545

Bone marrowalkyltransferase gene expression, murine,

1359

carcinoma cell removal, rhodamine 123,

621

liposomal annamycin toxicity. preclinical,

1369nascent DNA

9-aminocamptothecin effects. 1345

transplant

CsA and, combined with chemotherapy,

phase I clinical trial, 1495

Brain tumorsintracerebral rat 9L model

growth kinetics and treatment response.

MRI study, 643intracranial gliomas

gene therapy, MRI and H MRS study,651

VP-16-resistant cells

topoisomerase II, Bcl-2, and p53expression, 1391

DRCAJ

germline mutations and loss of

heterozygosity, early onset breast andovarian cancer, 539

Breastepitheliab cells

cytotoxic effects of adenovirus-mediated

wild-type p53 expression, 889

MDM2 mRNA expression, 71hypersensitivity to topoisomerase II

inhibitors, 49

Breast carcinomaadjuvant multicycle high-dose

chemotherapy, 715

advanced

amonafide treatment, Cancer andLeukemia Group B study. 699

thioTEPA combined with pentoxifylline,dose escalation, 791

vorozole therapy, phase II study, 287advanced metastatic

TGF-�3I circulation, 129

cathepsins B and L, prognostic value, 741

chromosome lq multiple genetic

alterations, 123clone 4 ER variant mRNA expression and,

155

early onset

get-mIme BRCAI mutations and loss of

heterozygosity, 539

ER�

c-myb posttranscriptional regulation, 235

insulin receptor substrate 1 ovenexpression,

1429

intraductal

gene alterations pattern, 261

invasive

chromosome 20q I 3 amplification,

prognostic implications, 1455

flow cytometric DNA analysis, 881

medical outcomes of care, health

maintenance organization and fee-for-

service patients, 179

metastatic

pirarubicin combined with 5-fluorouracil

and cycbophosphamide, phase II

study, 691

rapidly cycled high-dose alkylators,

1267

MRP expression, 1301

node-positive

bcl-2 protein expression and outcome,

I 89

p53mutations

CIPI/WAFJ expression, 907

tamoxifen resistance, 1203paclitaxel therapy. 247

P-glycoprotein phosphorylation, bryostatin

I and, 1581

postmenopausal

aromatase inhibition by letrozobe, 15 1 1

serum hepatocyte growth factorconcentrations, 1031

stage IV

ifosfamide and doxorubicin with rhG-

CSF, phase I study, I 85

tenascin expression, 1035

urokinase-type plasminogen activator

receptor. prognostic significance,1079

vascular endothelial growth factor and

platelet-derived endothelial cell

growth factor coexpression, 961WntS cloning, expression, and up-

regulation, 215

Breast carcinoma in situ

flow cytometric DNA analysis. 881

Broccolisalivary chemopreventive enzyme

induction, 1 153

Bryostatin 1and P-glycopnotein phosphonylation, breast

cancercells, 1581

Bystander effectcyclophosphamide/P450 2B1 gene therapy,

I 171

C

C225

biological efficacy, human tumor xenograft

model, 1311

CachexiahIL-6-induced, human uterine cervical

carcinoma xenograft, 1353CAl: see Carboxyamido.triazoleCamptothecin

9-aminocamptothecin derivative, phase I

and pharmacokinetic study, 269

water-insoluble congeners, preclinical

studies, 1235

Cancer: see CarcinomaCancer and Leukemia Group B studies

amonafide, advanced breast cancer, 699

TALl rearrangements. adult acute

lymphoblastic leukemia, 459

Carbohydrate-processing inhibitors, anticancer agents.

935

Carboplatin/etoposide

recombinant IL-3 before and after, phase I

trial, 1139

Carboxyamido-triazolemetabolism, human liver tissue and

humans, 399

oral, pharmacokinetics, 797

Carcinogenesis5-aza-2’-deoxycytidine-induced

phenylacetate suppression, 865

Carcinomaadvanced

ifosfamide and glutathione. 1525

anti-CD3 mAb and interleukin 2 therapyof, phase I study. 481

8-chloro-cyclic AMP immunological

effects, phase I clinical study, 377

human xenognafts

Bl(Fv)PE38 and Bl(dsFv)PE38immunotoxin characterizations, nude

mice, 1023

-induced gene

differential display identification, 1209

MRP expression. human. 1301

p53 antibodies, 1463

patient survival

histoculture drug-response assay and,

1537

removal from bone marrow, rhodamine

123, 621

Carcinoma, aerodigestiveretinoid chemoprevention, basic research

to clinics, 677

Carcinoma, bladderc-erb-B2 amplification. prognostic value.

1 189

MRP expression. 1301Carcinoma, breast

adjuvant multicycle high-dose

chemotherapy. 715

advanced

amonafide treatment, Cancer and

Leukemia Group B study, 699

thioTEPA combined with pentoxifylline,

dose escalation, 791

vorozole therapy, phase II study, 287

advanced metastatic

TGF-�3l circulation, 129

cathepsins B and L. prognostic value, 741

chromosome lq multiple genetic

alterations, 123

clone 4 ER variant mRNA expression and,

155

early onsetgermline BRCA1 mutations and loss of

heterozygosity. 539

ER�

c-mvb posttranscniptional regulation, 235

insulin receptor substrate 1 overexpression.

1429

invasive

chromosome 20q I 3 amplification.

prognostic implications, 1455

flow cytometnc DNA analysis, 881

Clinical Cancer Research 1649

MDM2 mRNA expression. 71

medical outcomes of cane, health

maintenance organization and fee-for-

service patients. I 79

metastatic

pinanubicin combined with 5-fluorouracil

and cyclophosphamide, phase II

study. 691

rapidly cycled high-dose alkylatons,

I 267

MRP expression. 1301

node-positive

hcl-2 protein expression and outcome,

189

p53 mutations

C1Pl/WAI:1 expression. 907

tamoxifen resistance, I 203

paclitaxel therapy, 247

P-glycopnotein phosphonylation, bryostatin

1 and. 1581

postmenopausal

aromatase inhibition by letrozole, 151 1

serum hepatocyte growth factor

concentrations, 1031

stage IV

ifosfamide and doxonubicin with nhG-

CSF, phase I study, 185

tenascin expression, 1035

urokinase-type plasminogen activator

receptor. prognostic significance.

1079

vascular endothebial growth factor and

platelet-derived endothelial cell

growth factor coexpression, 961

Wnt5 cloning. expression. and up-

regulation, 215

Carcinoma, cervicalhlL-6-induced cachexia, human xenograft,

1353

HSP7O levels, 1217

Carcinoma, colonalkyltransfenase activity. 519

antibody to ras proteins. 1071

chemotherapy response. mutant K-ras and,

441

N’ ,N’ ‘ -diethylnorspermine efficacy

against, preclinical. 847

EGF-R expression

and metastatic potential. 19

FUna and IFN-�3, 1337

iododeoxyuridine radiosensitization

modulation by 5 ‘-aminothymidine and

leucovorin, 407

metastasis-related genes. multiparametnic

i,? situ mRNA hybridization analysis.

I 095

metastatic

‘3’ 1-labeled CC49 with deoxyspergualin.

pilot radioimmunothenapy trial, 1503

MRP expression. 1301

stage II

bcl-2 oncoprotein expression. prognosticvalue, I 103

thymineless death

2’-deoxyadenosine-5’-triphosphate/

thymidine-5’-triphosphate ratio and,

723

Carcinoma, colorectaladvanced

schedule-selective biochemical

modulation of FUra. 955

c-met ovenexpression and amplification.

147

5-fluorounacil prodrug therapy, 839

ornithine decanboxylase and prognosis. 665

recombinant immunotoxin C242F(ab’ )-

PE38QQR, 1015

lIMP-I RNA expressionand liver metastases, 899

Carcinoma, endometrialand tamoxifen, 467

Carcinoma, epithelial ovarianadvanced

tumor-infiltrating lymphocyte adoptive

immunotherapy. 501

progesterone receptor content

I 1q22 loss of heterozygosity and, 945

Carcinoma, gastrointestinaltelomerase activity, 1245

Carcinoma, head and neckCD34� cells. 95

Carcinoma, hematologicalradioimmunothenapy, problems and

progress. 1439

Carcinoma, hepaticautoantibody to DNA topoisomerase II.

417

Carcinoma, kidneyMRP expression, 1301

Carcinoma, liverautoantibody to DNA topoisomerase II,

417

Carcinoma, lower respiratory tractp53 mutations, 763

Carcinoma, non.small cell lungadvanced

TRA/IFN-a, phase II study. 973

chromosome 9p2 1 homozygous deletions.

687

chronic oral etoposide pharmacology. I 517

MRP expression. 1301

p15 and p16 mutations, 687

Carcinoma, ovarianactivating factor. characterization. I 223

advanced

dose intensity. 575

autocnine endothelin- 1 growth factor

effects, 1059

CD44 heterogeneity. 333

cisplatin and JM216 transport, 981

DF3-P expression. 565

N’ .N’ ‘ -diethylnorspermine efficacy

against. preclinical, 847

early onset

genmline BRCAI mutations and loss of

hetenozygosity, 539

ganciclovir sensitization, HSV-TK gene.

1571

HSP27 expression, 1603

MRP expression. 1301

Carcinoma, pancreaticenbB-3 expression. 1413

Carcinoma, prostaticcell invasion

prostate-specific antigen facilitation.

I 089

cell kinetic changes. 473

chromosome 7q3 1 loss of heterozygosity.

I 385

DNA sequence amplification

identified by chromosome

microdissection, prognostic

implications. I I

DU-145 cellsurokinase-type plasminogen activator.

retinoic acid modulation. 747

matrix degradation

inhibition by retinoic acid, 755

MRP expression. 1301

p53 nuclear protein expression. prognostic

marker, 1295

vitamin D receptor expression, 24-

hydroxylase activity, and growth

inhibition by la,25-dihydroxyvitamin

D3, 997

Carcinoma, renalMRP expression. 1301

Carcinoma, renal cellEGF-R and TGF-a expression. 913

MDRI expression, 1611

Carcinoma, small cell lungchronic oral etoposide pharmacology. 1517

lysis

Lys3-bombesin and mAb 22immunoconjugate induction. 425

Carcinoma, squamous cellEGF-R ectodomain, 551

esophageal

MRP expression, 1301

p53 mutations, MDM2 amplification.

and HPV infection, 769

head and neck

cell kinetics, 527

end-stage, pretreatment p53 expression

and. 1407

GM-CSF-secreting, CD34� cells, 95mAb E48 biodistnibution, 277

p16 and p53 loss of heterozygosity and

mutations, 1043

predictive and prognostic markers, 1375

tumor targeting. mAb U36. 591

lung

K-ras mutations, 359

radiation-induced proliferation with EGF,

1557

Carcinoma, testicularMRP expression. 1301

Carcinoma, transitional cellbladder

human papillomavinus, 435tumor-associated antigens, prognostic

factors. 1195

Carcinoma, upper respiratory tractp53 mutations, 763

Carcinoma in situ, breastflow cytometnic DNA analysis. 881

Carcinomatous meningitisLMB- I dosage effect on survival, rat

model, 1545

Cathepsin Bprognostic value, human breast cancer,

741

Cathepsin Lprognostic value, human breast cancer.

741

Cationsrhodamine 123

removing carcinoma cells from bone

marrow. 621

CC49‘31t-labeled, and deoxyspergualin.

metastatic colon carcinoma, 1503

1650 Subject Index

I 77Lu-labeled, advanced adenocarcinoma,

1447

CD3mAb

combined with interleukin 2, therapy,

481

CD151gM mAb

serotherapy, acute myeloid leukemia,

965

CD33antibody, X anti-CD64

acute myeboid leukemia cell lysis, 1319

humanized mAb Ml95

cytotoxicity, myclogenous leukemia, 63

CD34

head and neck cancer, 95

CD44

heterogeneity, ovarian cancer, 333

splice variant expression, cervical

epithelium, 1 125

CD64

antibody, X anti-CD33

acute mycloid leukemia cell lysis, 1319

-dependent lysis

induction by Lys3-bombesin and mAb

22 immunoconjugate, small cell lung

carcinoma, 425

Cell cyclescheckpoints, 1994 Forbeck Cancer Forum,

1067

control of apoptosis, nitrogen mustard, 873

uveal melanoma, and prognosis, 41Cell death: see also Apoptosis

thymineless

2’-deoxyadenosine-S’-triphosphate/

thymidine-5’-tniphosphate and, colon

carcinoma, 723

Cell kineticshead and neck cancer, 527

human prostatic cancer, 473

Cell proliferationradiation-induced

with EGF, human squamous cancer

cells, 1557

rate, head and neck cancers, 527

c-erb-B2amplification

prognostic value, bladder carcinoma,

I 189

Cervical carcinomahIL-6-induced cachexia, human xenograft,

1353

HSP7O levels, 1217

Cervix, uterineepithelium

CD44 splice variants expression, I 125

HSP7O expression, 1217

C242F(ab’)-PE38QQRrecombinant anti-colonectal cancer

immunotoxin, 1015

CGS 20267aromatase inhibition, postmenopausal

breast cancer patients, I S I 1

Chemopreventionoltipraz, pharmacokinetics and

pharmacodynamics, I 133

phenylacetate, 865

retinoid, aerodigestive cancer, 677

salivary enzymes, induction, 1 153

Chemoradiation therapyhead and neck squamous cell carcinoma,

predictive and prognostic markers,

I 375

Chemoresistance: see also ResistanceWAFI/CipI levels and, acute myelogenous

leukemia, 1051

Chemosensitivityacute myeloid leukemia

in vivo interleukin 3 and, 295

ChemosensitizationP-glycopnotein, SCID human myeloma

xenograft model, 1563

Chemotherapycarboplatin!etoposide

recombinant IL-3 before and after,

phase I trial, 1139

combined with CsA and bone marrow

transplant, phase I clinical trial, 1495

cranial irradiation and, rodent model, 731

dose intensity, advanced ovarian cancer,

575

multicycle high-dose, breast cancer, 715

pinarubicin combined with 5-fluorouracil

and cycbophosphamide, metastatic

breast cancer, 691

response

mutant K-ras and, colon cancer, 441

Chimeric antibodyanti-EGFR (C225), human tumor xenograft

model, 1311

Chimeric proteinsC242F(ab’)-PE38QQR

recombinant anti-colorectal cancer

immunotoxin, 1015

hIL-l 3-PE38QQRhuman glioma sensitivity, 1253

8-Chboro-cyclic AMPphase I clinical study, 377

tumor cell growth inhibition, 1612-Chloro-2’-deoxyadenosine

cellular pharmacokinetics, leukemia, 385

resistance, lymphoid cell lines, 391

Chloroethylnitrosoureas

cytotoxicity

ada gene therapy, munine bone marrow,

1359

Chromosome microdissectionDNA sequence amplification identification,

prostate cancer, 1 1

Chromosome lqmultiple alterations, breast cancer, 123

Chromosome 7q31loss of heterozygosity, prostate cancer,

1385

Chromosome 9p2lhomozygous deletions, non-small cell lung

cancers, 687

loss of heterozygosity and mutations, head

and neck squamous cell carcinoma,

1043

Chromosome 11q22loss of heterozygosity and progesterone

receptor content, epithelial ovarian

cancer, 945

Chromosome l’7pl3loss of heterozygosity and mutations. head

and neck squamous cell carcinoma,

1043

Chromosome 20q13amplification, invasive breast cancer, 1455

CIPJIWAFJ

mRNA expression. breast carcinoma with

p53 mutations, 907

Cisplatin

combined with liposome-encapsulated

muramyl tripeptide

phosphatidylethanolamine, canine

osteosancoma, I 595

dose intensity, advanced ovarian cancer,

575

resistance

plasma membrane protein, ovarian

carcinoma cell lines, 981

transport, ovarian carcinoma cell lines, 981

c-juninduction

and apoptosis, human acute leukemia

cells, 559

Clone 4 estrogen receptor variantmRNA expression, and breast cancer, 155

CloningAIDS-related Kaposi’s sarcoma, 257

WntS, human breast cancers, 215

c-met

ovenexpression and amplification.

colorectal cancer, 147

c-mybposttranscriptional regulation, ER� breast

cancer cells, 235

Coffeesalivary chemopreventive enzyme

induction, 1 153

Colon adenocarcinomaFUra-leucovonin activity, xenografts, 33

Colon carcinomaalkyltransfenase activity, 519

antibody to ras proteins. 1071

chemotherapy response, mutant K-ras and,441

N’ ,N’ ‘ -diethylnorspermine efficacy

against, preclinical, 847

EGF-R expression

and metastatic potential, 19

FUra and IFN-�3, 1337

iododeoxyuridine radiosensitization

modulation by 5’-aminothymidine and

leucovonin, 407

metastasis-related genes, multiparametric

in situ mRNA hybridization analysis,

1095

metastatic

‘3’ 1-labeled CC49 with deoxyspergualin,

pilot radioimmunotherapy trial, 1503

MRP expression, 1301

stage II

bcl-2 oncoprotein expression, prognostic

value, 1103

thymineless death

2’-deoxyadenosine-5 ‘-tniphosphate/

thymidine-5’-tniphosphate ratio and,

723

Colony-stimulating factor 1and endometnial adenocarcinoma

etiopathogenesis, 313

Colorectal carcinoma

advanced

schedule-selective biochemical

modulation of 5-fluonouracil, 955

c-met overexpression and amplification,

147

5-fluorouracil prodrug therapy, 839

Cisplatin

Clinical Cancer Research 1651

ornithine decarboxylase and prognosis. 665

recombinant immunotoxin C242F(ab’)-

PE38QQR. 1015

TIMP-l RNA expressionand liver metastases, 899

Colorectal lesionstelomenase activity, 1245

Colorectal tumorigenesiselevated RNase L levels, 1421

Cranial irradiationand chemotherapy, rodent model, 731

Cryopreservationtumor-infiltrating lymphocytes

adoptive immunotherapy. advanced

epithelial ovarian cancer, 501

Cyclic AMP-dependent protein kinase type Itopoisomerase II inhibitor hypersensitivity,

human breast cells, 49

Cyclin-dependent kinases

inhibitor CIPI/WAFJ expression. breast

carcinoma with p53 mutations. 907

Cyclophosphamidecombined with pirarubicin and 5-

fluorouracil, metastatic breast cancer,

691

Cyclophosphamide/cytochrome P450therapy. bystander effect, I I 71

Cyclosporine A

and bone marrow transplant

combined with chemotherapy. phase I

clinical trial, 1495

Cysteine proteasescathepsins B and L. breast cancer. 741

Cytarabinecellular metabolism, modulation by G-

CSF, 169

Cytochrome P450 2B1cyclophosphamide gene therapy, bystander

effect, 1171

Cytokine responsemultilamellar vesicle muramyl tnipeptide

phosphatidylethanolamine treatment,

493

Cytotoxicitychloroethylnitrosourea

ada gene therapy. murine bone marrow,

1359

humanized mAb M195. myelogenous

leukemia, 63

monocyte

multilamellar vesicle muramyl tripeptide

phosphatidylethanolamine treatment,

493

water-insoluble camptothecin congeners,

preclinical studies, 1235

D

D1694antitumor effects, soft tissue sarcoma cell

lines. 631

D54 cellstopoisomerase II, Bcl-2, and p53

expression. 1391

Death: see also Apoptosisthymineless

2’-deoxyadenosine-S ‘-triphosphate/

thymidine-5’-tniphosphate and, colon

carcinoma cells, 723

2’-Deoxyadenosine-S’-triphosphate/

thymidine-5’-triphosphate

and thymineless death, colon carcinoma

cells, 723

2’-Deoxycytidine kinase deficiencyand 2-chloro-2’ -deoxyadenosine resistance,

lymphoid cell lines. 391

Deoxyribonucleoside 5’-triphosphateand thymineless death, colon carcinoma

cells. 723

Deoxyspergualin

‘ U I-labeled CC49 combined with,

metastatic colon carcinoma, I 503

DF3-Pexpression. human ovarian carcinomas,

565

cis-Diamminedichloroplatinum(II): see

Dibezineantileukemic effects. 823

5,10-Dideazatetrahydrofolic acidantitumor effects, soft tissue sarcoma cell

lines. 631

(6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic

acidwith oral folic acid supplement.

2B1 phanmacokinetics, 1479

I ,N’ ‘ -Diethylnorspermineantitumor efficacy, preclinical. 847

Differential displayhuman carcinoma-induced gene

identification, I 209

3,4-Dihydro-2-amino-6-methyl-4-oxo-5-(4-

pyridylthio)-quinazolonedihydrochloride

pharmacokinetics and pharmacodynamics.

24-hour study. 1275

N-5-[N-(3,4-Dihydro-2-methyl-4-

oxoquinazolin-6-ylmethyl)-N-

methylaminoj-2-thenoyl-L-glutamic

acid: see D1694Dihydropyrimidine dehydrogenase

tumonal target for fluorouracil modulation,

991

la,25-Dihydroxyvitamin D3growth inhibition, prostatic carcinoma cell

lines, 997

DNA

nascent bone marrow

9-aminocamptothecin effects, 1345

DNA analysisflow cytometnic, breast cancers, 881

DNA fragmentationhigh molecular weight, leukemia cell

apoptosis. 1005

DNA sequence amplificationchromosome microdissection, human

prostate cancer, 1 1

DNA topoisomerase Iinhibitors, mutagenic activity. 369

DNA topoisomerase IIautoantibody, liver cancer. 417

expression. VP- 16-resistant cells, 1391

inhibitors

hypersensitivity. human breast cells, 49

Dose intensityadvanced ovarian cancer, 575

Doxorubicin

combined with ifosfamide and rhG-CSF.

stage IV breast cancer, 185

metabolism, sublethal liver injury and, 351

Drug resistance: see Multidrug resistanceDrugs

histocultune response assay

and cancer patient survival, 1537

clinical applications. 305

-induced apoptosis

c-jun induction and, human acute

leukemia cells, 559

-resistant solid tumors

chemotherapy combined with CsA and

bone marrow transplant. phase I

clinical trial, 1495

DT-diaphorasesalivary, induction, 1 153

DU-145 cellsurokinase-type plasminogen activator

retinoic acid modulation, 747

Ductal carcinoma in situ

flow cytometnic DNA analysis. 881

Dyspla.siacervical epithelium

CD44 splice variants expression. 1 125

E

E48biodistribution, head and neck cancer, 277

Ectodomainepidenmal growth factor receptor,

squamous cell carcinoma, 551

EGFR: see Epidermal growth factorreceptor

Endoglinvascular endothelial cell up-regulation,

human solid tumors, 1623

Endometrial adenocarcinomaetiopathogenesis. colony-stimulating factor

I and, 313

Endometrial carcinomaand tamoxifen, 467

Endothelial cellsimmunotoxins targeting

-mediated vascular leak syndrome. 1589

vascular

endoglin up-regulation. human solid

tumors, 1623

Endothelial growth factorvascular

expression, breast cancer, 961

Endothelin-1autocnine growth factor effects, ovarian

carcinoma cells, 1059

Enzymes

chemopreventive salivary. induction, 1 153

Eosinophils

activation

IL-4 therapy, 805

Epidermal growth factorradiation-induced proliferation, human

squamous cancer cells, 1557

receptors

4.5-bis(4-fluoroanilino)phthalimide

inhibitor, in vivo antitumor effects,

813

chimeric antibody, biological efficacy,

human tumor xenognaft model. 13 1 1

ectodomain, squamous cell carcinoma,

551

expression, and metastatic potential,human colon carcinoma cells, 19

expression, prostatic neoplasms, 545

1652 Subject Index

expression, renal cell carcinoma, 913

mAb 528, tumor cell growth inhibition,

161

mutant, immunotoxins that target, 859

Epithelial cells

mammary

cytotoxic effects of adenovirus-mediated

wild-type p53 expression, 889

MDM2 mRNA expression, 71

Epithelial ovarian canceradvanced

adoptive immunotherapy with tumor-

infiltrating lymphocytes, 501

progesterone receptor content

1 1q22 loss of heterozygosity and, 945

Epithelium, cervicalCD44 splice variants expression, I 125

Epitopes

DF3-P

expression, human ovarian carcinomas,565

ER: see Estrogen receptorerbB-2

expression, lung adenocarcinoma, 659

erbB-3expression, pancreatic cancer, 1413

Escherichia coliada gene therapy, munine bone marrow,

1359

Esophageal squamous cell carcinomaMRP expression, 1301

p53 mutations, MDM2 amplification, and

HPV infection, 769

Estrogengrowth and transformation requirements

insulin receptor substrate 1

overexpression and, MCF-7 cells,

1429

receptor

clone 4 variant, mRNA expression, and

breast cancer, 155

-positive breast cancer cells, c-myb

posttranscriptional regulation, 235

Etoposide

chronic oral

pharmacology, small cell and non-small

cell lung cancer, 1517

combined with carboplatin

recombinant IL-3 before and after,

phase I trial, 1139

30-minute infusion, phase I study, 105

resistance

topoisomerase II, Bcb-2, and p53expression, brain tumor cell lines,

1391

Exotoxins

Pseudomonas

human IL-13-, human gliomasensitivity, 1253

immunotoxins containing, -mediated

vascular leak syndrome, 1589

recombinant F(ab’) C242-, anti-

coborectal cancer immunotoxin, 1015

Experimental intracranial tumors

gliomas

gene therapy, MRI and ‘H MRS study,

651

rat 9L model

growth kinetics and treatment response,MRI study, 643

F

F(ab’),E48

biodistribution, head and neck cancer,

277

F(ab’) C242-Pseudomonas exotoxinrecombinant anti-colorectal cancer

immunotoxin, 1015

FcyRImAb 22 against

Lys3-bombesin immunoconjugate

induction of lysis, small cell lung

carcinoma, 425

Fee-for-service plansmedical outcomes of care for breast

cancer, 179

Fenretinide: see N-(4-

Hydroxyphenyl)retinamide

Fibroblast growth factor

basic

levels, Wilms’ tumor, 327

Fibroblasts

dermal cultures, response to fractionated

radiation, 785

Filgrastim-mobilized peripheral blood progenitor

cells, breast cancer, 715

rapidly cycled high-dose alkylators,

metastatic breast cancer, 1267

Flow cytometryDNA analysis, breast cancers, 881

Fludarabinecellular metabolism, modulation by G-

CSF, 169

5-Fluorouracilcombined with cyclophosphamide and

pirarubicin, metastatic breast cancer,

691

combined with IFN-�3, human colon

carcinoma cells, 1337

combined with beucovorin, colon

adenocarcinoma xenografts, 33

combined with recombinant IFN-a, phase

I study, 615

modulation

dihydropyrimidine dehydnogenase

tumonal target, 991

schedule-selective, advanced colorectal

cancer, 955

prodrug, coborectal cancer, 839

Folate-based purine inhibitors

antitumor effects, soft tissue sarcoma

cell lines, 631

Folic acidoral supplement

lometrexol with, pharmacokinetics. 1479

Forbeck Cancer Forum on Cell CycleCheckpoints

1994 meeting report, 1067

FUra: see 5-FluorouracilFusion proteins

PML/RARs, acute pnomyelocytic

leukemia, 583

Fv immunotoxinsBl(dsFv)PE38 and Bl(Fv)PE38

characterization, human carcinoma

xenografts in nude mice, 1023

G

Ganciclovirsensitization

HSV-TK gene, ovarian carcinoma cells,

1571

toxicity

gene therapy, MRI and ‘H MRS study,

651

Gastric lesionstebomerase activity, 1245

Gastrointestinal cancertelomerase activity, 1245

G-CSF: see Granulocyte colony-

stimulating factorGene therapy

ada, munine bone marrow, 1359

cyclophosphamide/P450 2B1

bystander effect. I 171

experimental intracranial gliomas. MRI

and ‘H MRS study, 651

Genes: see also Oncogenesbcl-2

protein expression, and node-positive

breast cancer outcome, 189

alkyltransfenase

expression, murine bone marrow, 1359

BRCAI

get-mIme mutations and loss of

hetenozygosity. early onset breast and

ovarian cancer, 539

CIPI/WAFI

mRNA expression, breast carcinoma

with p53 mutations, 907

c-met

overexpression and amplification.

colorectal cancer. 147

c-mvb

posttranscriptional regulation. ER

breast cancer cells, 235

H-ras

mutations, lung cancer, 359

HSV-TK

gancicbovin sensitization, ovarian

carcinoma cells, 1571

and MDRI, retroviral coexpression, 447recombinant adenoviral-mediated

transfer, experimental intracranialgliomas, MRI and ‘H MRS study,

651

human carcinoma-induced

differential display identification, 1209

IGF-ll

loss of imprinting, prostate, 1471

K-ras

mutations, and chemotherapy response,

colon cancer, 441

mutations, lung cancer, 359

MDM2

amplification, esophageal squamous cell

carcinoma, 769

expression, breast epithelial cells, 71

MDRJcombined with P-glycoprotein.

ovenexpression, acute myeloid

leukemia, 81

expression, renal cell carcinoma, 161 1

and herpes simplex virus thymidine

kinase gene. netnovinal coexpression,

447

-transduced cells, selective killing by

Clinical Cancer Research 1653

coexpression of MDRI and herpes

simplex virus thymidine kinase gene.

447

metastasis-related

multiparametnic ut sitI� mRNA

hybridization analysis, colon

carcinoma, I 095

MRP

expression, human cancers, 1301

ovcrexpnession. acute myeloid leukemia,

81

p15mutations, non-small cell lung cancers,

687

p16

loss of hetenozygosity. head and neck

squamous cell carcinoma, 1043

mutations. head and neck squamous cell

carcinoma. 1043

mutations. non-small cell lung cancers.

,)53

687

cell cycle control, nitrogen mustard. 873

loss of heterozygosity. head and neck

squamous cell carcinoma, 1043

mutations. and tamoxifen resistance.

breast cancer. I 203

mutations. breast carcinoma with. CIPI/

WAFI expression. 907

mutations. esophageal squamous cell

carcinoma, 769

mutations. head and neck squamous cell

carcinoma. l()43

mutations. metastatic prostate cancer,

1111

mutations. upper and lower respiratory

tract carcinoma, 763

PAX5

expression. astrocytomas. 207

PML

RARn fusion protein. acute

promyelocytic leukemia. 583

ra.s

and chemotherapy response. colon

cancer, 441

TALl

rearrangements. adult acute

lymphoblastic leukemia. Cancer and

Leukemia Group B study, 459

Wnt5

cloning. expression. and up-regulation.

human breast cancers, 215

Gliomaexperimental intracranial

gene therapy. MRI and ‘11 MRS study.

651

hlL-l3-PE38QQR sensitivity. 1253

IL- I 3 receptor ovenexpression. I 253

p53 autoantibodies. 775

p53 imniunoreactivity. prognostic

significance. 1617

Glutathioneifosfamide and. advanced cancers. 1525

Glutathione S-tnansfenases

salivary. induction, I 153

GM-CSF: see Granulocyte-macrophagecolony-stimulating factor

Golgi carbohydrate processinginhibitors, anticancer agents, 935

Granulocyte colony-stimulating factor

cytarabine and fludarabine cellular

metabolism modulation, 169

recombinant human

if�sfamide and doxorubicin with, stage

IV breast cancer, I 85

Granulocyte-macrophage colony-stimulating factor

-secreting cancers

CD34 � cells. 95Growth factor withdrawal

-induced apoptosis

prevention by PML/RAR#{128}s. acute

promyelocytic leukemia. 583

Growth factorsautocnine endothelin- 1 effects, ovarian

carcinoma cells. 1059

epidermal

radiation-induced proliferation with,

human squamous cancer cells. 1557

hepatocyteserum concentrations, breast cancer,

I031

insulin-like. II

loss of imprinting, prostate. 1471

platelet-derived cndothelial cell

expression, breast cancer, 961

transforming. a

expression. pnostatic neoplasnis. 545

expression. renal cell carcinoma. 913

transforming. �

expression, AIDS-associated Kaposi ‘sarcoma. 1 119

receptors expression. AIDS-associated

Kaposi’s sarcoma. 1 1 19

transforming, 131

circulation, advanced metastatic breast

cancer and normal human plasma.

129

vascular endothelial

expression. breast cancer, 961

H

HBT-20 cellstopoisomerase 11. BcI-2. and p53

expression. 1391

HBT-28 cellstopoisonierase II. Bcl-2, and p53

expression. 1391

HCT-8 cellsFUra and IFN-�3, 1337

HCT-116 cells9-aminocamptothecin effects on nascent

bone marrow DNA. 1345Head and neck squamous cell carcinoma

CD34 cells. 95

cell kinetics, 527

end-stage

pretreatment p53 expression and. 1407

mAb E48 biodistnibution, 277

p16 and p53 loss of heterozygosity and

mutations. 1043

predictive and prognostic markers, 1375

tumor targeting

mAb U36, 591

Health maintenance organizationsmedical outcomes, breast cancer care, 179

Heat shock protein 27

expression, ovarian cancer, 1603

Heat shock protein 70

expression, uterine cervix, I 217

Hemangiosarcoma, splenicliposome-encapsulated muramyl tripeptide

phosphatidylethanolamine adjuvant

immunotherapy. canine, I 165

Hematological cancerradioimmunotherapy. problems and

progress. 1439

Hematopoietic reconstructionnew approaches. 3

Hepatic cancerautoantibody to DNA top()isomerase II,

417

Hepatocyte growth factorreceptor

Met gene overexpression and

amplification. colorectal cancer. 147

serum concentrations. breast cancer, 1031

Herpes simplex virus thymidine kinasegene

ganciclovir sensitization. ovarian

carcinoma cells. 1571

and MDRI, retnoviral coexpression. 447

recombinant adenoviral-mediated transfer

experimental intracranial gliomas. MRI

and ‘ H MRS study. 651

Heterozygosity, loss ofBRCAI. early onset breast and ovarian

cancer. 539

chromosome 7q3 I . prostate cancer. I 385

chromosome I 1q22, epithelial ovarian

cancer, 945

intraductal breast neoplasms. 261

j)16 and p53. head and neck squamous cell

carcinoma, 1043

Heterozygotesataxia telangiectasia. and fractionated

radiation. 785

High molecular weight-melanoma associated antigen

mimicry by mouse anti-idiotypic inAb

MK2-23. malignant melanoma. 705

Histoculture drug-response assayand cancer patient survival, 1537

clinical applications, 305

HL-60 cellsdifferentiation

enhancement by N-(4-

hydroxyphenyl)retinamide combined

with netinoic acid, 637

elimination by monoclonal antibodies.

athymic nude mouse leukemia model,

I 179

H-rasmutations. lung cancer. 359

HSP: see Heat shock proteinHuman papillomavirus

infection. esophageal squamous cell

carcinoma, 769

transitional cell carcinoma, urinary

bladder. 435

24-Hydroxylaseactivity, prostatic carcinoma cell lines. 997

N-(4-Hydroxyphenyl)retinamidecombined with retinoic acid

enhancement of differentiation and

retinoylation. 637

Hypersensitivity: see also Sensitivitytopoisomerase II inhibitors. human breast

cells. 49

1654 Subject Index

I

Ifosfamidecombined with doxorubicin and rhG-CSF

stage IV breast cancer, phase I study,

I 85

and glutathione. advanced cancers, 1525

IL: see InterleukinImaging

tumor receptor, Workshop Report, 921

Immune responseantimouse

modulation by deoxyspergualin.

metastatic colon carcinoma, I 503

Immune suppressionhead and neck cancer, 95

ImmunoconjugatesLys3-bombesin and mAb 22

lysis induction, small cell lung

carcinoma, 425

Immunoglobulin Amunine antitransfernin receptor antibody

42/6, phase Ia trial, I 259

Immunoglobulin GmAb E48

biodistribution, head and neck cancer,

277

mAb U36

tumor targeting, head and neck cancer,

591

Immunoglobulin Gichimenized with mAb 225

biological efficacy, human tumor

xenograft model. I 3 1 1

Immunoglobulin MmAb PM-81

serotherapy, acute myeboid leukemia.

965

ImmunoreactivityPS3’ glioma, 1617

Immunotherapy: see also

Radioimmunotherapyadjuvant

liposome-encapsulated muramyl

tripeptide phosphatidylethanolamine,

canine splenic hemangiosarcoma,

I 165

adoptivestem cell transplantation and, immediate

posttransplant, 607

tumor-infiltrating lymphocytes,

advanced epithelial ovarian cancer,

501

mouse anti-idiotypic mAb MK2-23,

malignant melanoma, 705

Immunotoxinsanti-colorectal cancer

recombinant C242F(ab’)-PE38QQR,

1015

B 1(dsFv)PE38

characterization, human carcinoma

xenognafts in nude mice, 1023

B1(Fv)PE38

characterization, human carcinoma

xenografts in nude mice, 1023

LMB-l (B3-LysPE38)

dosage effect on survival, carcinomatousmeningitis rat model, 1545

-mediated vascular leak syndrome, 1589

mutant epidermal growth factor receptor.

859

Imprinting, loss ofIGF-lI. prostate. 1471

In situ hybridization

multiparametnic mRNA analysis

metastasis-related genes, colon

carcinoma, 1095

InfectionsHPV, esophageal squamous cell

carcinoma, 769

Injury

liver

and doxorubicin metabolism, 351

Insulinreceptor substrate I overexpression. breast

cancer, 1429

Insulin-like growth factor IIloss of imprinting, prostate, 1471

a-Interferoncombined with trans-netinoic acid,

advanced non-small cell lung cancer.

973

recombinant

combined with FUna, phase I study, 615

a2a-InterferonFUra-leucovorin potentiation, colon

adenocarcinoma xenografts, 33

s-Interferoncombined with FUra, human colon

carcinoma cells, 1337

Interleukin 2combined with anti-CD3 mAb, phase I

study, 481

combined with IL-4, phase I trial, 1 145

mAb M 195 cytotoxicity enhancement,

myelogenous leukemia, 63

Interleukin 3

it? Vivo

impact on acute myeloid leukemia, 295recombinant

phase I trial, Southwest Oncology

GroupStudy, 1139

Interleukin 4combined with IL-2, phase I trial, 1 145

eosinophil activation, cancer patients. 805

Interleukin 6human

-induced cachexia, human uterine

cervical carcinoma xenognaft. I 353

Interleukin 13human

-Pseudotnonas exotoxin, human glioma

sensitivity, I 253

receptors

ovenexpnession, human glioma cells,

1253

Intracerebral tumorsrat 9L model

growth kinetics and treatment response,

MRI study. 643

Intracranial gliomas

gene therapy, MRI and ‘H MRS study,

651

Intraductal breast neoplasmsgene alterations pattern, 261

Invasive carcinoma, breastchromosome 20q 13 amplification,

prognostic implications, 1455

flow cytometric DNA analysis. 881

Invasive carcinoma, prostate

prostate-specific antigen facilitation, 1089

Invasive carcinoma, squamous cell

head and neck

predictive and prognostic markers, 1375

Iododeoxyuridineradiosensitization

5’-aminothymidine and leucovonin

modulation. human colon cancer

cells, 407

Irradiationcranial, and chemotherapy

delivery and toxicity. rodent model, 731

J

JM216: see Bis-acetato-ammine-

platinum(IV)

K

Kaposi’s sarcoma

AIDS-related

clonality. 257

TGF43 and TGF-�3 receptors expression.

I 119

Kidney carcinomaMRP expression. 1301

Kinases

cyclic AMP-dependent

topoisomerase II inhibitor

hypersensitivity. human breast cells,

49

cyclin-dependent

inhibitor CIPI/WAFI expression, breast

carcinoma with p53 mutations, 907

modulators

and taxol-induced apoptosis. human

lcukcniic cells. 1399polyanion inhibition. I 13

thymidine, herpes simplex virus gene

ganciclovir sensitization, ovarian

carcinoma cells, 1571and MDRI, retroviral coexpression, 447

recombinant adenoviral-niediated

transfer. experimental intracranial

gliomas. 651

K-rasmutations

and chemotherapy response. colon

cancer, 441

lung cancer, 359

L

Lesions, colorectal

telomerase activity. 1245

Lesions, gastrictelomerase activity. 1245

Letrozolearomatase inhibition. postmenopausal

breast cancer patients. 15 1 I

Leucovorincombined with 5-fluorouracil, colon

adenocarcinoma xenografts. 33

iododeoxyunidine radiosensitization

niodulation, human colon cancer

cells. 407

Leukemiaapoptosis

1051

Clinical Cancer Research 1655

high molecular weight DNA

fragmentation. I 005

taxol-induced, protein kinase modulators

and, 1399

cellular 2-chloro-2’-deoxyadenosine

pharmacokinetics. 385

elimination by monoclonal antibodies.

athymic nude mouse leukemia model,

I 179

MOLT-4 cells

cycle control. nitrogen mustard, 873

norsegoline and dibezine effects against.

823

Leukemia, acutedrug-induced apoptosis

c-jolt induction and, 559

Leukemia, acute lymphoblasticadult

TALl rearrangements, Cancer and

Leukemia Group B study, 459

Leukemia, acute myelocyticMRP expression. 1301

Leukemia, acute myelogenousG-CSF therapy

cytarabine and fiudarabine cellular

metabolism modulation, I 69

WAF1/Cipb levels, and chemoresistance,

Leukemia, acute myeloid1gM mAb PM-81 serotherapy. phase I

clinical trial, 965

it? VItO interleukin 3 effects, 295

lysis. bispecific antibody 251 X 22. 1319

multidrug resistance, 81

proteolyzed a,-antitnypsin, 199

Leukemia, acute promyelocyticPML/RARa fusion protein. 583

Leukemia, chronic lymphocyticMRP expression, 1301

Leukemia, myelogenoushumanized mAb M195 cytotoxicity, 63

Leukocytes

peripheral blood

poly(adenosine diphosphonibose)

polymerase. 223

Le�’ damageimmunotoxins targeting

-mediated vascular leak syndrome. I 589

Lipophilic cationsrhodamine 123

removing carcinoma cells from bone

marrow. 621

Liposome-encapsulated muramyl tnipeptide

phosphatidylethanolamine

canine splenic hemangiosarcoma. 1 165

combined with cisplatin therapy, canine

osteosarcoma, I 595

monocyte cytotoxicity and cytokine

response, 493

-incorporated annamycin, preclinical

toxicity. 1369

LiverCAb metabolism, 399

metastases

colonectal cancer TIMP-l RNA

expression and, 899

sublethal injury

and doxonubicin metabolism, 351

Liver cancerautoantibody to DNA topoisomerase II.

417

LMB-ldosage effect on survival, carcinomatous

meningitis rat model. 1545

Lometrexolwith oral folic acid supplement.

phanmacokinetics. 1479

Loss of heterozygosity

BRCAJ. early onset breast and ovarian

cancer. 539

chromosome I 1q22, epithelial ovarian

cancer, 945

chromosome 7q3 I , prostate cancer, I 385

intraductal breast neoplasms. 261

j�16 and p53. head and neck squamous cell

carcinoma. 1043

Loss of imprinting

IGF-11. prostate. 1471

Lower respiratory tract carcinomap53 mutations, 763

-labeled CC49

phase I study, advanced

adenocancinoma, I 447

Lung adenocarcinomaN’.N’ ‘-diethylnorspermine efficacy

against. preclinical. 847

erhB-2 and p53 oncogene expression. 659

Lung carcinomaK-ra.s mutations. 359

non-small cell

advanced, TRA!IFN-a, phase II study.

973

chronic oral etoposide pharmacology.

1517

MRP expression. 1301

p15 and p16 mutations. 687

9p2 I homozygous deletions, 687

small cell

chronic oral etoposide pharmacology.

1517

lysis. induction by Lys3-bombesin and

mAb 22 immunoconjugate. 425

Lymph nodemetastases

colorectal cancer TIMP- I RNA

expression and, 899

Lymphocytes

apoptosis

cell cycle control. nitrogen mustard, 873

tumor-infiltrating

adoptive immunotherapy. advanced

epithelial ovarian cancer. 501Lymphoid cells

2-chloro-2’-deoxyadenosine resistance, 391

Lymphoma, T-cell

anti-idiotype therapy, immune responses.

I 285

Lys3-bombesinmAb 22 immunoconjugate

lysis induction. small cell lung

carcinoma. 425

Lysis

acute myeboid leukemia cells

bispecific antibody 251 X 22, 1319

small cell carcinoma of lung cells

Lys3-bombesin and mAb 22

immunoconjugate induction, 425

M

Magnetic resonance imaginggene therapy of experimental intracranial

gliomas. 651

intracerebral nat 9L brain tumors. 643

Magnetic resonance spectroscopyproton

gene therapy of experimental

intracranial gliomas. 651

Malignancy

melanoma

mouse anti-idiotypic mAb MK2-23

immunotherapy. 705

peripheral blood leukocytes

poly(adenosine diphosphonibose)

polymerase. 223

superficial tumors

thenmoradiotherapy. I 39

Mammary epithelial cells

cytotoxic effects of adenovinus-mediated

wild-type p53 expression. 889

MDM2 mRNA expression. 71

Matrix degradationinhibition by retinoic acid, prostatic

carcinoma cells, 755

MCF-7 cellsinsulin receptor substrate I overexpression.

1429

MDM2

amplification. esophageal squamous cell

carcinoma. 769niRNA expression, breast epithelial cells,

71

MDRJcombined with P-glycoprotein

overexpression. acute mycloid leukemia,

81

expression, renal cell carcinoma, 161 1

and herpes simplex virus thymidine kinase

gene

retroviral coexpression. 447

-transduced cells

selective killing by coexpression of

MDRI and herpes simplex virus

thymidine kinase gene. 447

MelanomaN’,N’ ‘-diethylnonspermine efficacy

against. preclinical. 847

malignant

mouse anti-idiotypic mAb MK2-23

immunotherapy. 705

MRP expression. 1301

T-cell receptor signal transduction

molecule alterations, I 327

T-cell receptor-c chain loss, I 327Melanoma, ocular

OM432MUllet-ian inhibiting substance cleavage

and antiproliferative effects. 343

Melanoma, uvealcell cycling and prognosis. 41

Meningitiscarcinomatous

LMB-l dosage effect on survival, ratmodel, 1545

Messenger RNA

bicistronic netnovinus vectors

coexpression of MDRJ and herpes

simplex virus thymidine kinase gene.

447

1656 Subject Index

CIPJ/WAFJ expression, breast carcinoma

with p53 mutations, 907

clone 4 ER variant

expression, and breast cancer, 155MDM2

expression, breast epithelial cells, 71

multiparametric in situ hybridization

analysis

metastasis-related genes, colon

carcinoma, 1095

Metabloproteinase 1tissue inhibitor

RNA expression, colorectal cancer, andliven metastases, 899

Metastasis

breast canceradvanced, TGF-�3 I circulation, 129

pirarubicin combined with 5-fluorouracil

and cycbophosphamide, phase II

study, 691

rapidly cycled high-dose alkylatons,

1267

colon carcinomaitllabeled CC49 with deoxyspergualin.

pilot radioimmunothenapy trial, 1503liver

colorectal cancer TIMP- 1 RNA

expression and, 899

prostate cancer

p53 mutations, 1 1 1 1

-related genes

multiparametnic in situ mRNA

hybridization analysis. colon

carcinoma, 1095Metastatic potential

epidermal growth factor receptor bevels

and, human colon carcinoma cells, 19

Met/HGFreceptor gene overexpression and

amplification. cobonectal cancer, 147

Methotrexateresistance

antitumor effects of antifolate inhibitors,

soft tissue sarcoma cell lines, 6319-Methoxy-N,N-dimethyl-5-

nitropyrazolo[3,4,5-kI]acridine-2(6H)-propanamine

pharmacokinetics, mice, 831

phase I clinical trial, 1487

Microdissectionchromosome

DNA sequence amplification identifiedby. prostate cancer, prognosticimplications, 1 1

MK2-23

mouse anti-idiotypic mAb, malignant

melanoma immunotherapy, 705MOLT-4 cells

apoptosis

cell cycle control. nitrogen mustard, 873

Monoclonal antibody

anti-CD3

combined with interleukin 2, therapy.

481

anti-CD33 (humanized mAb M195)

cytotoxicity, myelogenous leukemia, 63

anti-CDI5 (PM-81)

serothenapy, acute myeloid leukemia,

965anti-EGFR

chimerized with IgGl. biological

efficacy. human tumor xenograft

model, 1311

tumor cell growth inhibition. 161

anti-Fc’yRI (mAb 22)Lys3-bombesin immunoconjugate. lysis

induction, small cell lung carcinoma.

425

CC49

, 3 ‘ I-labeled, and deoxyspengualin,

metastatic colon carcinoma, 1503

I 77Lu-labeled, advancedadenocarcinoma, 1447

DF3-P

epitope expression. human ovarian

carcinomas. 565

E48biodistribution, head and neck cancer,

277

leukemia elimination, athymic nude mouse

leukemia model, I 179

MK2-23

immunotherapy. malignant melanoma,

705

U36tumor targeting, head and neck cancer,

591Monocytes

cytotoxicity, multilamellar vesicle

muramyl tripeptide

phosphatidylethanolamine treatment,

493

-mediated lysis

acute myeloid leukemia cells, bispecific

antibody 251 x 22, 1319

small cell carcinoma of lung cells. Lys3-

bombesin and mAb 22immunoconjugate induction, 425

MRP

expression. human cancers. 1301

overexpression. acute mycloid leukemia,

81

Mtillerian inhibiting substancecleavage and antiproliferative effects, 343

Multidrug resistancefunctional phenotype, acute myeloid

leukemia, 81

gene expression, renal cell carcinoma,

1611

HSV-TK retrovinal coexpression. 447

P-glycoprotein phosphorylationbryostatin 1 and. breast cancer cells,

1581

Multilamellar vesicle muramyl tripeptidephosphatidylethanolamine therapy

monocyte cytotoxicity and cytokine

response, 493

Muramyl tripeptidephosphatidylethanolamine

liposome-encapsulated

canine splenic hemangiosarcoma. I I 65

combined with cisplatin therapy, canine

osteosarcoma, 1595monocyte cytotoxicity and cytokine

response. 493

Murine Double Minute 2: see MDM2

Murine monoclonal antibody CC49immune response

deoxyspergualin modulation, metastatic

colon carcinoma, 1503

I 77Lu-labeled, advanced adenocarcinoma,1447

Mutationsepidermal growth factor receptor.

immunotoxins, 859

germline

BRCAI. early onset breast and ovarian

cancer, 539

H-ras. lung cancer. 359

K-ras

and chemotherapy response. colon

cancer, 441

lung cancer, 359

p16. head and neck squamous cell

carcinoma, 1043

p53breast carcinoma CIPI/WAFJ

expression. 907

esophageal squamous cell carcinoma.

769

head and neck squamous cell carcinoma,

1043

metastatic prostate cancer. 1 1 1 1

and tamoxifen resistance, breast cancer,

1203

upper and lower respiratory tract

carcinoma, 763

MyelomaP-glycopnotein chemosensitization. SCID

human xenograft model. I 563

N

National Cancer Institute Workshop

proceedings. tumor receptor imaging. 921

Natural killer cells

activated

stem cell transplantation and

immunotherapy. immediate

posttransplant. 607

Neoplasms: see also TumorsCD44 splice variants expression. cervical

epithelium. 1125

gene alterations pattern. intraductal breast.

261

telomerase activity, gastric and colorectal

lesions, I 245

Neutrophils

-mediated lysis

Lys3-bombesin and mAb 22

immunoconjugate induction, small

cell lung carcinoma, 425

Nitrogen mustard

apoptosis cell cycle control. 873

Non-small cell lung cancer

advanced

TRA!IFN-a, phase II study. 973chromosome 9p2 I homozygous deletions,

687

chronic oral etoposide pharmacology. 1517

MRP expression. 1301

p15 and p16 mutations. 687

Norsegoline

antileukemic effects, 823

NSC 366140: see 9-Methoxy-N,N-

dimethyl-5-nitropyrazolo[3,4,5-kllacridine-2(6H)-propanamine

NSC 609974: see CAlNuclear protein

p53expression, prostate cancer, 1295

Nucleoside analogue

-induced apoptosis

Clinical Cancer Research 1657

expression. breast cancer, 96 I

high molecular weight DNA

fragmentation. leukemia cells, 1005

Nucleotides

2-chloro-2 ‘-deoxyadenosine

cellular pharmacokinetics, leukemia, 385

0

Ocular melanomaOM432

MOllenian inhibiting substance cleavage

and antiproliferative effects, 343

Oligoadenylate

2’,5’-linked

-dependent RNase L. elevated levels,

colonectal tumorigenesis. 1421

Oltiprazchemoprevention. pharniacokinetics and

pharmacodynamics. 1 133

0M432Mullet-ian inhibiting substance cleavage

and antiproliferative effects. 343

Oncogenes: see also Genes; Proto-

oncogenesc-erb-B2

amplification prognostic value. bladder

carcinoma, 1189

c-jut?

induction, and apoptosis, human acute

leukemia cells, 559

c-metovenexpression and amplification.

colorectal cancer, 147

erhB-2

expression, lung adenocarcinoma, 659

H-ras

mutations. lung cancer, 359

K-ras

mutations, and chemotherapy response.

colon cancer, 441

mutations, lung cancer. 359

p53

expression, lung adenocarcinoma, 659

Oncoprotein: see also Proteinbcl-2

expression. and node-positive breast

cancer outcome. 189expression. stage II colon carcinoma.

I 103

expression. VP- I 6-resistant cells, I 391

OncotoxinsTP4O

superficial bladder cancer. phase I

clinical study. 57

Ornithine decarboxylaselevels, cobonectal carcinoma, 665

Osteosarcomaliposome-encapsulated muramyl tnipeptide

phosphatidylethanolainine and

cisplatin therapy, dogs. 1595

Ovarian carcinomaactivating factor. characterization. I 223

advanced

dose intensity, 575

advanced epithelial

tumor-infiltrating lymphocyte adoptive

immunotherapy. 501

autocrine endothelin- I growth factor

effects, 1059

CD44 heterogeneity, 333

cisplatin and JM2I6 transport. 981

DF3-P expression. 565N’,N’ ‘-diethylnorspermine efficacy

against. pneclinical. 847

early onset

get-mIme BRCAI mutations and loss of

heterozygosity, 539

epithelial

progesterone receptor content, I I q22

loss of heterozygosity and. 945

ganciclovir sensitization. HSV- TK gene.

1571

HSP27 expression. 1603

MRP expression, I 301

p15

P

mutations, non-small cell lung cancers,

687

p16loss of heterozygosity. head and neck

squamous cell carcinoma, 1043

mutations

head and neck squamous cell carcinoma.

1043

non-small cell lung cancers, 687

p53expression

cell cycle control, nitrogen mustard. 873

lung adenocarcinoma. 659

loss of heterozygosity. head and neck

squamous cell carcinoma. l()43

mutations

breast carcinoma CIPI/WAFI

expression. 907

esophageal squamous cell carcinoma,

769

head and neck squamous cell carcinoma.

1043

metastatic prostate cancer, I 1 1 1

and tamoxifen resistance. breast cancer.

1203

upper and lower respiratory tract

carcinoma, 763

p53 proteinantibodies. various cancer types. I 463

autoantibodies. glioma, 775

expression

pretreatment, and end-stage squamous

cell carcinoma of head and neck.

1407

VP-I6-nesistant cells. 1391

immunoreactivity. glioma. 1617

nuclear expression. prostate cancer, I 295

wild-type

adenovinus-mediated expression.cytotoxic clThcts. niammany epithelial

cells, 889

Paclitaxelbreast cancer therapy, 247

pharmacokinetics and pharmacodynamics.

3-hour infusion versus 24-hour

infusion, 599

Pancreatic cancererbB-3 expression. 1413

Papillary renal cell carcinomaEGF-R and TGF-a expression, 913

PAXSexpression. astrocytomas. 207

p26BCL-2human leukemic cells

taxol-induced apoptosis. protein kinase

modulators and. 1399

PD1 15934pharmacokinetics. mice, 831

phase I clinical trial. 1487

Pentoxifyllinecombined with thioTEPA

dose escalation, advanced breast cancer.

791

PE38QQRC242F(ab’)-

recombinant anti-colorectal cancer

immunotoxin. 1015

hIL-13-

human glioma sensitivity. 1253

Peripheral bloodleukocytes

poly(adenosine diphosphonibose)

polynierase. 223

progenitor cells

filgrastim-mobilized. adjuvant treatment,

breast cancer. 7 IS

rapidly cycled high-dose alkylators

supported by. metastatic breast

cancer, I 267

stern cells

autologous transplantation and

immunotherapy. immediate

posttransplant. 607

P-glycoproteinchemosensitization, SCID human myeloma

xenograft model, I 563

combined with MDRIoverexpression. acute myeloid leukemia.

81

phosphorylation

bryostatin I and. breast cancer cells,

I 581

Phenylacetate

chemoprevention. 865

Phosphatidylethanolamineliposome-encapsulated muramyl tnipeptide

canine splenic hemangiosarcoma. 1 165

combined with cisplatin therapy. canine

osteosarcoma. I 595

monocyte cytotoxicity and cytokine

response, 493

PhosphorylationP-glycoprotein

bryostatin 1 and. breast cancer cells.

I �81

Pirarubicincombined with 5-fluorouracil and

cyclophosphamide, metastatic breast

cancer, 691

Plasma

TGF43I circulation, normal human. 129

Plasma membrane proteincisplatin resistance, ovarian carcinoma cell

lines. 981

Plasminogen activatorurokinase-type

receptor. prognostic significance. breast

cancer, 1079

netinoic acid modulation, DU-l45 cells,

747

Platelet-derived endothelial cell growth

factor

1658 Subject Index

Platinumdose intensity, advanced ovarian cancer,

575

PM-Siserotherapy, acute myeloid leukemia, 965

PMLJRARa

fusion protein, acute pnomyebocytic

leukemia, 583

Poly(adenosine diphosphoribose)polymerase

peripheral blood leukocytes, 223

Polyamine analoguesN’ ,N’ ‘ -diethylnorspermine

antitumor efficacy. preclinicab, 847

Polyanionsprotein kinase C inhibition, 1 13

Preneoplasia

gastric and colorectal lesions

tebomerase activity. I 245

Prodrugs5-fluorouracil. colorectal cancer therapy.

839

Progenitor cellsperipheral blood

fligrastim-mobilized, breast cancer, 715

rapidly cycled high-dose alkylatonssupported by, metastatic breast

cancer, 1267

Progesterone

receptor

I 1q22 loss of heterozygosity and,

epithebial ovarian cancer, 945

Prostateboss of imprinting, IGF-II, 1471

Prostate.specific antigenhuman prostate cancer cell invasion

facilitation, 1089

Prostatic carcinomacell invasion

prostate-specific antigen facilitation,

1089

cell kinetic changes, human, 473

chromosome 7q3 1 loss of hetenozygosity.I 385

DNA sequence amplification

identified by chromosome

microdissection, prognostic

implications. I 1

DU-l45 cells

urokinase-type plasminogen activator,retinoic acid modulation, 747

matrix degradation

inhibition by netinoic acid, 755

metastatic

p53 mutations, I I I 1MRP expression, 1301

p53 nuclear protein expression, prognostic

marker, 1295progression

EGF-R and TGF-cs expression, 545vitamin D receptor expression. 24-

hydroxylase activity, and la,25-dihydnoxyvitamin D3 growth

inhibition, 997

Protein: see also Oncoproteinchimenic

C242F(ab’)-PE38QQR, recombinant

anti-colorectal cancer immunotoxin,

1015

hIL-13-PE38QQR, human glioma

sensitivity, 1253

differentiation and retinoylation

enhancement by N-(4-

hydroxyphenyl)retinamide combined

with retinoic acid, 637

expression. breast epithelial cells. 71

fusion

PML/RARa, acute promyelocytic

leukemia, 583

p53antibodies, various cancer types, 1463

autoantibodies, glioma, 775

expression, VP-16-resistant cells, 1391

immunoreactivity, glioma. 1617

nuclear expression, prostate cancer,

I 295

pretreatment expression, and end-stagesquamous cell carcinoma of head and

neck, 1407

wild-type. adenovirus-mediated

expression. cytotoxic effects,mammary epithelial cells, 889

ras

antibody, colon cancer. 1071

WAF1/Cipllevels and chemoresistance, acute

myelogenous leukemia. 1051

Protein kinasemodulators

and taxol-induced apoptosis, humanleukemic cells. 1399

Protein kinase Cpolyanion inhibition, 1 13

Protein kinase type I

cyclic AMP-dependent

topoisomerase II inhibitor

hypersensitivity, human breast cells,

49Proton magnetic resonance spectroscopy

gene therapy of experimental intracranial

gliomas. 651

Proto-oncogenesc-,nvb

posttranscniptional regulation, ER

breast cancer cells, 235

Pseudomonas exotoxin

F(ab’) C242-recombinant anti-colorectal cancer

immunotoxin, 1015

human IL-13-

human glioma sensitivity, 1253immunotoxins containing

-mediated vascular leak syndrome, I 589

Purine

folate-based inhibitors

antitumor effects, soft tissue sarcoma

cell lines, 631

Pyrazoloacridinepharmacokinetics, mice, 831

Pyrazoloacridine NSC366140phase I clinical trial, 1487

PZA: see Pyrazoloacridine

R

R83842: see VorozoleRadiation

-induced proliferation

with EGF, human squamous cancer

cells, 1557Radioimmunoscintigraphy

mAb U36, head and neck cancer, 591

Radioimmunotherapyhematological cancer

problems and progress, 1439

‘ 3’ I-labeled CC49 with deoxyspergualin

pilot trial, metastatic colon carcinoma,

I 503

Radiosensitizationiododeoxyuridine

S ‘-aminothymidine and leucovonin

modulation, human colon cancer

cells, 407

Radiotherapyfractionated

fibroblast response. 785

ras

antibody. colon cancer, 1071

rasand chemotherapy response, colon cancer,

441

Rat 9L brain tumor modelgrowth kinetics and treatment response.

MRI study. 643

Receptorscolony-stimulating factor I

and etiopathogenesis of endometnial

adenocarcinoma, 313

epidenmal growth factor

4.5-bis(4-fluoroanilino)phthalimide

inhibitor. in l’i�’() antitumor effects,

813

chimeric antibody to. biological

efficacy. human tumor xenograft

model, 1311

ectodomain, squamous cell carcinoma,

�

expression. and metastatic potential.

human colon carcinoma cells. 19

expression, prostatic neoplasms. 545

expression. renal cell carcinoma. 913mAb 528 against. tumor cell growth

inhibition, 161

mutant, immunotoxins that target, 859

estrogen

clone 4 variant mRNA expression, and

breast cancer. 155

-positive breast cancer cells. c-,nvb

posttranscniptional regulation. 235

hepatocyte growth factor

Met gene ovenexpression and

amplification. colorectal cancer, 147

insulin, substrate I

overexpression, breast cancer, 1429

interleukin- I 3

ovenexpnession. human glioma cells.

1253

progesterone

1 1q22 loss of heterozygosity and,

epithelial ovarian cancer, 945

retinoic acid, a

PML fusion protein. acute

promyclocytic leukemia, 583

T-cell

signal transduction molecule alterations,

melanoma, I 327

T-cell, -� chain

loss, melanoma. I 327

transfemn

murine immunoglobulin A antibody 42/6

against, phase Ia trial, 1259

transforming growth factor �3

Clinical Cancer Research 1659

expression. AIDS-associated Kaposi ‘s

sarcoma, 1119

tumor

imaging. Workshop Report. 921

unokinase-type plasminogen activator

prognostic significance. breast cancer,

I079

vitamin D

expression. prostatic carcinoma cell

lines. 997

Renal carcinomaMRP expression. 1301

Renal cell carcinomaEGF-R and TGF-a expression. 913

MDRI expression. 161 1

Resistance: see also Chemoresistance2-chboro-2’-deoxyadenosine. lymphoid cell

lines, 391

cisplatin

plasma membrane protein. ovarian

carcinoma cell lines, 981

etoposide

topoisomerase II. Bcl-2. and p53

expression. brain tumor cell lines,

I 391

methotrexate

antitumor effects of antifolate inhibitors.

soil tissue sarcoma cell lines, 631

multidrug

functional phenotype. acute niyeloid

leukemia. 81

gene expression. renal cell carcinoma,

161 I

HSV-TK netrosiral coexpnession. 447

P-glycoprotein phosphorylation.

bryostatin I and, breast cancer cells,

1581

tamoxifen

j)53 mutations and. breast cancer. I 203

water-insoluble catnptothecin congeners.

preclinical studies, 1235

Respiratory tract carcinomap53 mutations. 763

Retinoic acidcombined with N-(4-

hydroxyphenyl)retinamide

differentiation and retinoylation

enhancement, 637

matrix degradation inhibition. prostatic

carcinoma cells. 755

receptor a

PML fusion protein. acute

promyelocytic leukemia, 583

unokinase-type plasminogen activator

modulation, DU-l45 cells, 747

aIl-tran.s-Retinoic acidcombined with a-interferon. advanced

non-small cell lung cancer, 973

Retinoid chemopreventionaerodigestive cancer, basic research to

clinics. 677

Retinoylationenhancement by iV-(4-

hydroxyphenyl)retinamide combined

with retinoic acid. 637

Retrovirus vectorsbicistronic niRNA

MDRI and herpes simplex virus

thymidine kinase gene coexpression.

447

Rhodamine 123removing carcinoma cells from bone

marrow, 621

RNA

TIMP- I expression, colorectal cancer

and liver metastases, 899

RNase L

elevated levels, colorectal tumonigenesis.

1421

S

Saliva

chemopreventive enzymes. induction, I 153

Sarcoma, Kaposi’s

AIDS-related

clonality. 257

TGF-�3 and TGF-�3 receptors expression.

I 119

Sarcoma, soft tissueantitumor effects of antifolate inhibitors.

631

MRP expression. 1301

SCID: see Severe combinedimmunodeficiency

Sensitivity: see also Hypersensitivity

I 43-D-arabinofuranosylcytosine. acute

mycloid leukemia, 81

htL-13-PE38QQR. human glioma cells.I 253

Sensitization

ganciclovir

HSV-TK gene. ovarian carcinoma cells,

I �71

Serine proteases

prostate-specific antigen

human prostate cancer cell invasion

facilitation, 1089

Serotherapy1gM mAb PM-81. acute mycloid leukemia.

965

Serumhepatocyte growth factor concentrations.

breast cancer, 1031

p53 autoantibodies, glioma. 775

Severe combined immunodeficiencyP-glycoprotein chemosensitization. human

myeboma xenograft model. I 563

Skin fibroblastsresponse to fractionated radiation, 785

Small cell carcinoma, lung

chronic oral etoposide pharmacology. 15 17

lysis

Lys3-bomhesin and mAb 22

immunoconjugate induction. 425

Soft tissue sarcoma

antitumor effects of antifolate inhibitors,

631

MRP expression. 1301

Solid tumorsN’ ,N’ ‘ -diethylnorspenmine efficacy

against. preclinical. 847

drug-resistant

chemotherapy combined with CsA and

bone marrow transplant. phase I

clinical trial, 1495endoglin up-regulation. vascular

endothelial cells. 1623

Southwest Oncology Group Studyrecombinant IL-3 phase I trial, I 139

Splenic hemangiosarcoma

liposome-encapsulated muramyl tnipeptide

phosphatidylethanolamine adjuvant

immunotherapy. canine. I I 65

Squamous cell carcinomaEGF-R ectodomain, 551

radiation-induced proliferation with EGF.

I 557

Squamous cell carcinoma, esophagealMRP expression. 1301

p53 mutations, MDM2 amplification. and

HPV infection, 769

Squamous cell carcinoma, head and neck

cell kinetics, 527

end-stage

pretreatment p53 expression and, I 407

GM-CSF-secreting

CD34 � cells, 95

mAb E48 biodistnibution, 277p16 and p53 loss of heterozygosity and

mutations, 1043

predictive and prognostic markers. I 375

tumor targeting

mAb U36, 591

Squamous cell carcinoma, lungK-ras mutations. 359

Stem cellsautologous peripheral blood

transplantation and immunotherapy.

immediate posttnansplant. 607

Superficial bladder canceroncotoxin TP4O, phase I clinical study. 57

tumor-associated antigens. prognostic

factors, I I 95

Superficial malignant tumorsthenmoradiotherapy. I 39

Suramincellular pharmacology, 509

-related polyanions

protein kinase C inhibition, 1 13

Swainsonineantitumor effects. 935

T

T cellsantigen

highly restricted. anti-idiotype antibody

mimicking. T-cell lymphoma therapy.

I 285

lymphoma

anti-idiotype therapy. immune

responses. 1285

receptor

signal transduction molecule alterations.

melanoma, I 327reccptor-� chain

loss, melanoma. I 327

TALlrearrangements. adult acute lymphoblastic

leukemia. Cancer and Leukemia

Group B study. 459Tamoxifen

advanced breast cancer therapy

vorozole efficacy and tolerability. phase

II study. 287

endometrial carcinoma and. 467

resistance

/)53 mutations and. breast cancer, I 203

Taxol-induced apoptosis

1660 Subject Index

protein kinase modulators and, human

leukemic cells, 1399

Technetium-99m-labeled mAb U36

tumor targeting, head and neck cancer,

591

Telomeraseactivity. gastric and colorectal lesions,

1245

Tenascinexpression, human breast cancer, 1035

Testis carcinoma

MRP expression, 1301

TF-1 cellsgrowth factor-induced apoptosis

prevention by PMLIRARa, acute

pnomyelocytic leukemia, 583

TGF: see Transforming growth factorThermoradiotherapy

of superficial malignant tumors, 139

ThioTEPAcombined with pentoxifylline

dose escalation, advanced breast cancer,

791

Thymidine-5’-triphosphate2 ‘-deoxyadenosine-5 ‘-triphosphate ratio

and thymineless death, colon carcinoma

cells, 723

Thymidylateantifolate inhibitors

AG337. 24-hour study, 1275

antitumor effects, human soft tissue

sarcoma cell lines, 631

Thymineless death2’-deoxyadenosine-S ‘-triphosphate/

thymidine-5 ‘-tniphosphate and, colon

carcinoma cells, 723

TIMP-1: see Tissue inhibitor of

metalloproteinase ITissue inhibitor of metalloproteinase i

RNA expression, coborectal cancer

and liven metastases, 899

Tolerabilityvorozole, advanced breast cancer, 287

Toxicitycranial irradiation and chemotherapy,

rodent model, 731ganciclovir

gene therapy, MRI and ‘H MRS study,

651

liposomal annamycin, preclinical, 1369

Toxins: see Immunotoxins; OncotoxinsTP4O

superficial bladder cancer, phase I clinical

study, 57

TRA: See trans-Retinoic acidTransfernn

receptor

murine immunoglobulin A antibody 42/

6 against, phase Ia trial, 1259

Transforming growth factor-aexpression

prostatic neoplasms, 545

renal cell carcinoma, 913

Transforming growth factor-aexpression, AIDS-associated Kaposi’s

sarcoma, 1 1 19Transforming growth factor-�31

circulation, advanced metastatic breast

cancer and normal human plasma,

129

Transitional cell carcinoma, bladderhuman papillomavirus. 435

tumor-associated antigens, prognostic

factors, 1195

Transplantation, bone marrow

combined with chemotherapy and CsA,

phase I clinical trial, 1495

Transplantation, stem celland immunotherapy, immediate

posttransplant. 607

N,N’,N”-Triethylenethiophosphoramide

combined with pentoxifylline

dose escalation, advanced breast cancer,

791

Tumor cell growthinhibition by 8-chloro-cyclic AMP and

anti-EGFR mAb, 161

proliferative rate, head and neck cancers,

527

Tumor progressionEGF-R and TGF-a expression, prostatic.

545

enbB-3 expression and, pancreatic cancer,

1413

Tumor targetingmAb U36, head and neck cancer, 591

Tumorigenesis, colorectal

elevated RNase L levels. 1421

Tumor-infiltrating lymphocytesadoptive immunotherapy, advanced

epithelial ovarian cancer, 501

Tumors: see also Neoplasms; specific

tumors-associated antigens

prognostic factors, transitional cell

bladder carcinoma, 1 195

4.5-bis(4-fluonoanilino)phthalimide effects

against, 813

carbohydrate processing inhibitor effects

against, 935

cytotoxic effects of adenovirus-mediated

wild-type p53 expression, mammary

epithelial cells, 889

N’ ,N’ ‘ -diethylnorspenmine efficacy

against, preclinicab. 847

estrogen growth and transformation

requirements. MCF-7 cells, 1429

killing

cycbophosphamide/P450 2B1 gene

therapy, 1171

progesterone receptor content

1 1q22 loss of heterozygosity and,

epithelial ovarian cancer, 945

receptors

imaging. Workshop Report, 921

superficial malignant

thenmoradiothenapy, 139

xenograft

biological efficacy of chimenic antibody

to EGFR, human model, 1311

Tumors, brainintracerebral rat 9L model

growth kinetics and treatment response.

MRI study. 643

intracranial gliomas

gene therapy, MRI and ‘H MRS study.

651

VP-l6-nesistant cells

topoisomerase II, Bcl-2, and p53

expression, 1391

Tumors, solid

drug-resistant

chemotherapy combined with CsA and

bone marrow transplant. phase I

clinical trial. 1495

endoglin up-regulation, vascular

endothelial cells, 1623

U36

U

tumor targeting, head and neck cancer,

591

183U89

antitumor effects, soft tissue sarcoma cell

lines, 631

Upper respiratory tract carcinoma

p53 mutations, 763

Urinary bladder: see BladderUrine

EGF-R ectodomain, squamous cell

carcinoma, 551

Urokinase-mediated matrix degradation. prostatic

carcinoma cells, 755

-type plasminogen activator

retinoic acid modulation, DU-I45 cells,

747

-type plasminogen activator receptor

prognostic significance, breast cancer,

I079

Uterine cervical carcinomahIL-6-induced cachexia, human xenograft,

I 353

HSP7O levels, 1217

Uterine cervix

epitheliumCD44 splice variants expression. 1 125

HSP7O expression. 1217

Uveal melanoma

prognosis

cell cycling and, 41

V

Vascular endothelial cells

endoglin up-regulation. human solid

tumors. I 623

Vascular endothelial growth factor

expression, breast cancer, 961

Vascular leak syndromeimmunotoxin-mediated, 1589

Vitamin Dreceptor expression, prostatic carcinoma

cell lines, 997

Vorozoleadvanced breast cancer therapy. phase II

study. 287

VP-16: see Etoposide

w

WAF1/Cipilevels and chemoresistance, acute

myelogenous leukemia. 1051

Wild-type alleleloss of

BRCAJ, early onset breast and ovariancancer, 539

Wild-type p53adenovirus-mediated expression

1563

Clinical Cancer Research 1661

cytotoxic effects, mammary epithelial

cells, 889

Wilms’ tumorbFGF levels. 327

Withdrawalgrowth factor

-induced apoptosis, prevention by PMIJ

RARa, acute promyelocytic leukemia. 583

WntScloning. expression, and up-regulation,

human breast cancers, 215

x

Xenografts

colon adenocarcinoma

FUra-leucovorin activity, 33

colonectal tumor

recombinant C242F(ab’)-PE38QQR

immunotoxin, 1015

human carcinoma

Bl(Fv)PE38 and Bl(dsFv)PE38

immunotoxin characterizations, nude

mice, 1023

human tumor model

biological efficacy of chimenic antibody

toEGFR. 1311

human uterine cervical carcinoma

hIL-6-induced cachexia, 1353

SCID human myeloma model

P-glycoprotein chemosensitization,

Clinical Cancer Research i

Instructions for Authors

Scope

Clinical Cancer Research, a new journal of the American

Association for Cancer Research. publishes original articles

describing clinical research on the cellular and molecular char-

actenization, prevention, diagnosis. and therapy of human can-

cer. Its focus is on innovative clinical research and translational

research which bridges the laboratory and the clinic. Clinical

Cancer Research is especially interested in clinical trials eval-

uating new treatments for cancer: research on molecular abnor-

malities that predict incidence. response to therapy. and out-

come: and laboratory studies of new drugs and biological

agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational

research in: molecular phantiiacology and chemotherapy: drug

sensitivity and resistance: tumor immunology and immunother-

apy: radiobiobogy and radiation oncology: solid tumor oncol-

ogy; hematological malignancies: surgical oncology : pediatric

oncology: molecular oncology and cancer genes: pathology.

markers, and prognostic indicators: growth factors. cytokines.

and signal transduction: bone marrow transplantation: gene

therapy: cancer endocrinology: cell adhesion, invasion, and

metastasis: prevention of primary and recurrent cancer: differ-

entiation and cell death: clinical genetics: and detection of

minimal disease.

Editorial Policy

When a manuscript is received for consideration. the Editors

assume that no similar paper has been on will be submitted for

publication elsewhere. Further, it is understood that all authors

listed on a manuscript have agreed to its submission. The

signature of the corresponding author on the letter of submis-

sion signifies that these conditions have been fulfilled.

Journal policy requires that authors. reviewers. and Asso-

ciate Editors reveal in a letter to the Editor-in-Chief any nela-

tionships that they have that could be construed as causing a

conflict of interest with regard to a manuscript under review.

The letter should include a statement of any financial relation-

ships with commercial companies involved with a product

under study.

Upon acceptance. authors must transfer copyright to the

American Association for Cancer Research, Inc. , the copyright

owner of the journal. prior to publication. The Editors endorse

the principles embodied in the Declaration of Helsinki and

expect that all investigations involving humans will have been

performed in accordance with these principles. A copy of the

Declaration is available from the American Medical Associa-

tion, P.O. Box 7046, Dover, DE 19903-7046. For animal cx-

perimentation reported in the journal. it is expected that inves-

tigators will have observed the Interdisciplinary Priiiciples and

Guidelines for the Use of Animals in Researci?, Testing. and

Education issued by the New York Academy of Sciences’ Ad

Hoc Committee on Animal Research. a copy of which is

available for $5.00 from the Marketing Department, New York

Academy of Sciences. 2 East 63rd Street, New York, NY

10021-7289. All human and animal studies must have been

approved by the investigator’s Institutional Review Board.

Review Process

The review process. expedited by fax transmission and over-

night mail service. is conducted as rapidly as possible. Each

submitted manuscript is reviewed by at least two experts in the

field of investigation. If the authors are invited to submit a

revised manuscript for an expedited further review, the revised

version must he submitted within three months.

Manuscript Submission

Send manuscripts to John Mendelsohn. M.D.. Editor-in-Chief.

Clinical Cancer Researcl?, at Department of Medicine, Memo-

nab Sloan-Kettering Cancer Center. 1275 York Avenue. New

York, NY 10021. Submit fouroriginal sets (not photocopies) of

figures along with four copies of the manuscript. If a manu-

script is closely related to papers that are in press on have been

submitted elsewhere. please provide copies of those papers

with your subiiiission.

Advances in Brief will be reserved for concise, definitive

reports of novel observations and discoveries that have unusual

importance. A request for consideration for Advances in Brief

should be included in the letter of submission. A Minireview is

a brief analysis (typically 3-4 printed pages) of a focused.

timely research topic, aimed at a multidisciplinary audience.

Minireviews and Controversies in Clinical Cancer Research

that are submitted on solicited will undergo editorial review.

The Editors welcome Letters to the Editor. which will he

published if they are determined to be appropriate.

The letter of submission should suggest the Associate

Editor (or Editor-in-Chief) who will serve as primary reviewer

of the manuscript. In addition, we invite authors to provide the

names. addresses, and telephone/fax numbers of up to five

potential reviewers who are not current or recent collaborators

or advisors in the area under investigation.

For both original and revised submissions, we cannot

guarantee that manuscripts and illustrations will be returned to

the author.

Format

Manuscripts must be written succinctly in clear, grammatical

English. Define abbreviations in an inclusive footnote to the

text. Double-space on 8 1/2 x 1 1-inch paper. Dot-matrix print-

ing is not acceptable. The format is as follows:

1. Title page. including title, authors and their institutions.

research support. and address plus telephone/fax numbers of

the corresponding author:

2. A running title of fewer than 50 characters:

3. Three to five key words that do not appear in the title:

4. Abstract. of not more than 250 words, stating briefly the

objectives. methods, results, and conclusions of the study:

5. Text arranged in this order: Introduction, Methods. Results,

Discussion, Acknowledgments. References:

ii Instructions for Authors

6. Footnotes, on a page separate from the text. Designate foot-

notes consecutively with superscript Arabic numerals;

7. Tables, on pages separate from the text, with descriptive

titles and legends that make the data understandable without

reference to the text;

8. Figure legends, on pages separate from the text, with descrip-

tive titles and explanations to make the data understandable

without reference to the text. Define all symbols and include

staining for halftones where applicable;

9. Figures.

References

Include only those articles that have been published or are in

press. Unpublished data or personal communications must be

cited as footnotes to the text. Personal communications should

be substantiated by a letter of permission. Number references in

the order of their first mention in the text. Cite only the number

assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:

1. Shaffer, D. W., Smith, L. S., Bums, H. A., Clark, G. M., Eckardt,

J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn,

J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oraletoposide with or without granulocyte-macrophage colony-stimulating

factor in patients with advanced malignancies. Cancer Res., 53: 5929-

5933, 1993.

2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal

antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L.

Longo (eds.), Cancer Chemotherapy and Biological Response ModifiersAnnual, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers

B. V., 1990.

labeled envelope, for distribution to reviewers. A typed label

placed on the reverse side of each figure should contain the

first author’s name, figure number, and an arrow indicating

top of figure. Letters and numbers on figures should not be

larger than 12-point type. All figures will be published at a

width of approximately 3 inches (8 cm) unless the author

requests a greater width. Use tissue overlays to indicate impor-

tant areas of the photographs that must be reproduced with

greater fidelity.

Authors are encouraged to submit color figures. The cx-

pense of reproducing color photographs will be charged to the

authors. Submit color figures on flexible backing.

Typesetting Manuscripts from Computer Disks

Clinical Cancer Research welcomes disks to expedite produc-

tion of accepted manuscripts. If your article is accepted for

publication, you will receive instructions regarding disk submis-

sion. It is the author’s responsibility to ensure that the material

on the disk matches the final accepted version of the manuscript.

For more information, contact:

John Mendelsohn, M.D., Editor-in-Chief. Clinical Cancer Re-

search, Department of Medicine, Memorial Sloan-Kettering

Cancer Center, 1 275 York Avenue, New York, NY 10021,

Telephone 21 2-639-63 17. Fax 212-717-3629

or:

Figures

Provide four original sets of figures (whether line-cut draw-

ings or halftones). Each sorted set should be in a separate

Publications Department, American Association for Cancer Re-

search, Public Ledger Building. Suite 816. 150 South Indepen-

dence Mall West, Philadelphia. PA 19106-3483, Telephone

215-440-9300, Fax 215-440-9355.

AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND

CORRESPONDING MEMBERSHIP

Notification of Candidate

MarchJulyNovember

Ass0

�. .,�� ‘1,5

� U:= .

BENEFITS OF MEMBERSHIPThe American Association for Cancer Research (AACR), a

scientific society of over 10,000 laboratory and clinical cancerresearchers, was founded in 1907 to facilitate communication anddissemination of knowledge among scientists and others dedicated

to the cancer problem; to foster research in cancer and relatedbiomedical sciences; to encourage the presentation and discussionof new and important observations in the field; to foster publiceducation, science education, and training; and to advance theunderstanding of cancer etiology, prevention, diagnosis, andtreatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) forconsideration for presentation at the AACR annual meeting;

2. an advance copy of the Program and Proceedings of the

American Association for Cancer Research pertaining to eachannual meeting;

3. reduced registration rates at annual meetings;

4. priority notice of small, focussed meetings in the AACR’sexciting series of Special Conferences in Cancer Research;

5. reduced registration rates for Special Conferences;

6. opportunities for participation in AACR meetings in NorthAmerica and abroad with other scientific societies around theworld;

7. receipt of AACR Newsletters and other important announce-

ments;8. early notification of and reduced rates for participation in the

AACR Employment Register;9. an up-to-date Membership Directory of thousands of research-

ers in the cancer field;

10. the professional benefits of AACR’s public education activitiesconcerning funding for cancer research and press coverage ofthe latest research findings;

11. participation in Summer Workshops that foster networkingopportunities and science education for young investigators;

and12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators wholive in the Americas. Individuals who have conducted two years ofresearch resulting in peer-reviewed publications relevant to cancer,or who have made substantial contributions to cancer research inan administrative or educational capacity, are eligible. If acandidate has conducted research in an area of biomedical sciencerelated to cancer, he or she will qualify for membership. Evidenceof patents relevant to cancer research may be submitted asqualifications for membership in lieu ofpeer-reviewed publications.

Corresponding membership is open to persons who are notresidents of the Americas. The qualifications for corresponding

membership are the same as those indicated above for activemembership. Visiting scientists from outside the Americas who

intend to return to their countries oforigin by the anticipated timeof election should apply for corresponding membership. All other

visiting scientists should apply for active membership and transfer

to corresponding status upon leaving the Americas.Graduate and medical students, postdoctoral fellows, and

physicians in training who do not yet meet the above qualifications

for active or corresponding membership should apply for associatemembership. Forms for associate membership are available fromthe AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membershipapplication: January 1, May 1, and September 1 ofeach year. The

Membership Committee will review all complete applications for

active membership that have been received by these deadlines andwill submit recommendations on each candidate to the Board ofDirectors which formally elects all members. The same procedureis followed by the Special Memberships Committee which receives

applications for corresponding membership. Candidates will be

notified according to the following schedule:

Receipt of Applicationin AACR Office ________________

January 1May 1September 1

A complete application consists of the following material:1. 6 copies of the form on the opposite side of this page, with all

requested information provided.2. 5 copies of the candidates most current curriculum vitae and

bibliography.

3. 5 copies of a letter of recommendation from a nominator whois an active, corresponding, emeritus, or honorary member of

the AACR (at least one copy must be a signed, original letter).This letter should describe the candidate’s achievements inlaboratory research, clinical investigations, or epidemiologicalresearch, and it should affirm that this research adheres toaccepted ethical scientific standards. -OR- The nominator maysupply the responses requested at the bottom of the applica-

tion form in the section entitled “STATEMENT OF SUPPORT”(at least one copy ofthe form must be the signed original).

4. 5 copies of a letter of recommendation as described in Item 3above from a seconder who is an active, corresponding,emeritus, or honorary member ofthe AACR (at least one copymust be a signed, original letter). -OR- The seconder may

supply the responses requested at the bottom of the applica-

tion form in the section entitled “STATEMENT OF SUPPORT”(at least one copy ofthe form must be the signed original).

5. 5 reprints of each of two publications on which the candidateappears as author. As noted above, evidence of patentsdeveloped by the candidate may be submitted in lieu ofone orboth of the publications. If submitting patents, supply patentnumber and year awarded.All material should be collated into five complete sets with the

original application form as a covering document and sent to theaddress given below. Questions regarding procedures for member-

ship application may also be directed to the following address:

American Association for Cancer ResearchPublic Ledger Building, Suite 816

150 S. Independence Mall WestPhiladelphia, PA 19106-3483

Phone: 215/440-9300FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIPCandidates should be aware ofthe following responsibilities of

membership in the AACR. Active members must pay annual dues.

In 1996 annual dues for active members are $160, $95 ofwhich isdesignated for AACRjournal subscriptions. Newly elected members

of the AACR who have already purchased subscriptions to Cancer

Research, Clinical Cancer Research, Cell Growth & Differentiation,or Cancer Epzdeniiology, Biomarkers & Pret’ention at the higher,nonmember rates will receive reimbursement ofthe unused portionof those subscriptions once their first year’s membership dues arepaid in full.

Corresponding members are required to pay dues ($80 in 1996

and may, if they wish, subscribe to Caticer Research, Clinical

Cancer Research , Cell Grou’th & Differentiation , or Cancer Epide-

tniologv, Biomarkers & Pret’ention at reduced member rates.

Applicants elected in March will be responsible for payment of

that year’s dues; applicants elected in July and November will pay

dues for the following year. Applicants elected in March and July

will be eligible to sponsor an abstract for the next annual meeting.Every effort will be made to afford the same opportunity to

applicants elected in November.

Margaret loti, PhI).

Executive I)irectoi’

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building . Suite 816 . 150 S. Independence Mall West . Philadelphia, PA 19106-3483

APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE:___________________________________________ DATE OF BIRTH:_________

LAST FIRST MI.

PRESENT POSITION/TITLE:

INSTITUTIONAL AFFILIATION:_______________________________________________________________

INSTITUTIONAL ADDRESS:

(City) (State/Province)

TELEPHONE NUMBER:___________________________

(Country) (Postal Code)

FAX NUMBER:_________________________

E-MAIL NUMBER

PRIMARY FIELD OF RESEARCH (Please check only one):

Biochemistry and Biophysics .........Biostatistics

Cellular Biology and Genetics ...............Clinical Investigations

...............Epidemiology .............Jmmunology

Preclinical Pharmacology and �Virology

Experimental Therapeutics

(CARRIER):_____________________________________

......Carcinogenesis

.Endocrinology

...............Molecular Biology and Genetics

............Other:____________________________________

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please li st most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this

application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If

submitting patents, supply patent number and year awarded.)

CANDIDATE CANDIDATE

NOMINATED BY*:___________________________ SECONDED BY*:__________________________

(Please print) (Please print)

CANDIDATE IS APPLYING FOR (Check one): E ACTIVE 11 CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT

Instead ofsubmitting letters ofrecommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer How long has the candidate worked in the field of cancer

research? years research? _____years

Will the candidate make a long-term contribution to cancer Will the candidate make a long-term contribution to cancer

research? Yes .......No research? Yes No

Does the candidate’s research adhere to accepted ethical Does the candidate’s research adhere to accepted ethical

standards? Yes No standards? Yes No

I therefore recommend this candidate for membership in the I therefore recommend this candidate for membership in the

American Association for Cancer Research. American Association for Cancer Research.

Signature of nominator’5 Date Signature of seconder* Date

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced. ) 8/95

AS�0,

, .. � �,,

1kCI�R %�

AMERICAN ASSOCIATION FOR CANCER RESEARCH

� GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP�

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical

students, postdoctoral fellows, and physicians in training who are

following a course of study oi’ who are working in a research

program relevant to cancer. Scientists in training who already

have a substantial record of publications may wish to apply for

active or corresponding membership which confers full benefits of

membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a

scientific society consisting of laboratory and clinical cancer

researchers, was founded in 1907 to facilitate communication and

dissemination ofknowledge among scientists and others dedicated

to the cancer problem; to foster research in cancer and related

biomedical sciences; to encourage presentation and discussion of

new and important observations in the field; to foster public

education, science education, and training; and to advance the

understanding of cancer etiology, prevention, diagnosis, and

treatment throughout the world. Associate members of the AACR

enjoy the following benefits:

1. the privilege ofsponsot’ing a paper for presentation at the AACR

annual meeting provided that (a) the associate member is the

presenter ofthe paper and )b) an active, corresponding, emeri-

tus, or honorary member in good standing of the AACR also

signs the abstract of the paper in support of the work (In this

instance, the member who cosigns the abstract does not lose his

or her own sponsorship privilege.);

2. an advance copy of the scientific Program and (if one has been

purchased by the associate member) the Proceedings of the

American Association for Cancer Research which contains

abstracts ofall papers being presented at each annual meeting;

3. the privilege of registering for the annual meeting at the low

student rate (This rate is otherwise available only to predoctoral

students.

4. preferred access to the AACR Employment Register;

5. optional subscriptions to the Association’s high-quality journals

Cancer Resea,’ch , Clinical Cancer Research, Cell Growth &

Differen tin tiwi , and Can cer Epideni iology, Biornarkers &

Pret’ention at reduced member rates;

6. priority notification of events in the AACR’s series of special

conferences on timely subjects in the field;

7. reduced registration rates at special conferences;

8. the receipt of AACR newsletters, meeting announcements, and

an up-to-date membership directory: and

9. the facilitation of informal scientific exchange with leading

researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the

official application form on the reverse side of these instructions.

Each candidate for associate membership must be nominated by an

active, corresponding, emeritus, or honorary member in good

standing of the AACR. Three completed copies of the form should

be submitted: at least one of these copies must carry the original

signatures ofboth the candidate and the nominator. The applica-

tion form may be submitted to the Association Office at any time.

After review of applications for associate membership, the

Executive Director will notify candidates of their election or

deferral within one month of the receipt of the application form.

A check for one year’s dues payment must accompany the applica-

tion. Dues are currently $35 for associate members residing in the

Americas and $45 for residents ofother countries. This fee will be

refunded to any candidate deemed to be ineligible for associate

membership. Checks should be in U.S. currency, made payable to

AACR, Inc. , and drawn on a U.S. bank. Send the three copies of

the application form and the $35 or $45 dues payment to:

American Association for Cancer Research

Public Ledger Building, Suite 816

150 S. Independence Mall West

Philadelphia, PA 19106-3483

215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be

determined by the AACR Board of Directors. Dues for 1995 and

1996 have been set at $35 per year for residents of the Americas

and $45 for residents of other countries. If an application is

submitted by August 31, the accompanying dues payment will be

credited to the current year. Candidates submitting applications

between September 1 and December 31 may indicate whether they

wish their dues payments credited to the current or forthcoming

year. Candidates should be aware, however, that associate

members may sponsor an abstract for the annual meeting only if

their dues for the current year are paid. For example, an associate

member submitting an abstract in November 1995 for the

forthcoming annual meeting must have paid dues for 1995. Any

newly elected associate members of the AACR who have already

purchased subscriptions to Cancer Research, Clinical Cancer

Research, Cell Growth & Differentiation , and Cancer Epidemiology,

Bio,narkers & Prevention at the higher, nonmember rate will

receive a refund for the unused portion of that subscription upon

receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an

invoice for dues for the forthcoming year. Payment of this invoice

must be accompanied by a statement signed by the associate

member’s current registrar, dean, or department head, verifying

the member’s current academic status. The Association’s By-Laws

state that dues are payable for each year in advance by January 1

of the year to which they should be applied. An individual may be

an associate member for a maximum of five years. Each year in

which an individual pays dues will count as one full year of

associate membership. Thus, an associate member who pays dues

for 1995 may retain associate membership until December 31,

1999. The Board ofDirectors may terminate the membership of an

associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building . Suite 816 . 150 S. Independence Mall West . Philadelphia, PA 19106-3483

NAME OF CANDIDATE:__________________________________________ DATE OF BIRTH:_________

LAST FIRST MI.

INSTITUTIONAL AFFILIATION:______________________________________________________________

INSTITUTIONAL ADDRESS:

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER:___________________________ FAX NUMBER:______________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER):___________________

Graduate Student ............Medical Student

...........Physician in Training Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

......,.,.Biochemistry and Biophysics ............Biostatistics .........Carcinogenesis..Cellular Biology and Genetics ...............Clinical Investigations ...Endocrinology

Epidemiology ....jmmunology Molecular Biology and Genetics

Preclinical Pharmacology and ...............Virology ____________________________________

Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of

receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on

which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY:__________________________________________________________

(Please type or print name ofAACR active member� in good standing.)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the

reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the

statements on this application are true.

Signature of Candidate:____________________________________________________________ Date:_________________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my

knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator’� :__________________________________________________________________ Date:___________________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator.

Enclose a check in U.S. funds, made payable to AACR, Inc. , and drawn on a U.S. bank for one year’s dues. Dues are currently $35

for associate members residing in the Americas and $45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the EJ current D forthcoming calendar year.

(NOTE: Ifdues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible

to sponsor an abstract for presentation at the annual meeting in March or April of that year. ) See Guidelines for Application on

the reverse side of this form for further instructions.

:sNominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced. ) 8/95

(this term mayhe reproduced.)

ADVANCE REGISTRATION FORM

AMERICAN ASSOCIATION FOR CANCER RESEARCH

87TH ANNUAL MEETING - WASHINGTON, DC - April 20-24, 1996

Return to

American Association for Cancer Research #{149}Public Ledger Building, Suite 816

150 S. Independence Mall West #{149}Philadelphia, PA 19106-3483 #{149}FAX: 215-440-7228

DEADLINES: #{149}March 1, 1996 for reduced rates and to ensure receipt of meeting materials by mail in late March on early April

#{149}March 25, 1996 for all registration by mail (Registration fom,ns received after this (late %t’ill not be accepted.

Registration oil! be conducte(l at (lie ‘vVas/iington Comivemition Center from April 20-24.

#{149}April 17, 1996 to cancel registration and receive refund less cancellation fee ($35)

(Please j,,#{149}int)

NAME: _______________________________________ ________________________________ ______________1_ast l�,istIN1dd!c Initta! AA(’R Mcrnhcr Number

TITLE: ______________________________ ADDRESS: __________________________________________________ln�.Lituti�n

Street. Building. �r P(�st 0111cc B�x

(‘itv Statc r Pruvince Z1p/P�sta1 (‘ode (‘�untry (ii n�t U.S.)

TELEPHONE NO.: ________________________________ FAX NO.: ______________________________________

0 Check this box if you have a physical disability and have special requirements for transportation, hotel accommodations. or other facilities in connection

with the fleeting. A member of the Association Staff will contact you.

WHAT IS YOUR PRIMARY FIELD OF RESEARCH (Please check only one):

0 ‘Biochemistry and Biophysics 0 2Carcinogenesis 0 Cellular Biology & Genetics 0 4Clinical Investigations

0 5Endocninology �J �Epidemiology � 7Expenirnental Therapeutics 0 Xlmmunology � Molecular Biology & Genetics

0 Prevention � #{176}Radiobiology/Radiation Oncology 0 Virology 0 ‘Other (please specify):

ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1996 AACR MEETING7 DYes DNo

ON WHICH DAYS WILL YOU ATTEND THE 1996 AACR ANNUAL MEETING?

0 Saturday. April 20 0 Sunday. April 21 D Monday. April 22 0 Tuesday. April 23 0 Wednesday, April 24

PAYMENT OF REGISTRATION

Fees may be paid by check or with a MasterCard, VISA, American Express, or Eurocard account. All payments must be made in U.S. currency, and all checksniust be drawn on a U.S. bank. Payment must accompany this form: purchase orders will not be accepted as payment.

On or Before AfterMarch 1 March 1 METHOD OF PAYMENT

0 Active/Corresponding Member Rate $135 $170 OCheck payable to AACR. Inc. in U.S. currency. drawn on a

0 Nonmember Rate S270 $340 U.S. hank

(includes copy of AACR Proceedings)

0 Emeritus Member Rate $ 50 $ 50D #{149} PersunhlnstItutI()n Issuing Check Cheek N�.Associate Member Rate S 75 S 85

0 Predoctonal Student Rate5 S 60 S 70

0 Honorary Member Rate S 0 S 0

0 AACR P1�o(�eedi!ig.s�’ $ 35 Members $ 35 Members D MasterCard 0 VISA 0 Atnencan Express 0 Eurocard

$ 45 Nonmembens S 45 Nonmembens

0 Optional Overseas Surcharge” S 25 NA.

0 Proceedings on C[)-ROM $ 35 Members $ 35 Members Card Number Expiration Date

S 45 Nonmembers S 45 Nonmembers

0 Methods Workshop Registration S 50 Members S 50 Members

S 75 Nonmembers S 75 Nonmembers ___________________________ ____________________Signature

TOTAL ENCLOSED OR CHARGEI) S_________ S________

‘An application for Associate Membership may accompany this form. hut these should he submitted well before the March 1 deadline. as review of the Associate Membership applicatioitmay delay registrittion.

�Stttdcnts niust enclose a statemettt. signed by lie registrar. dean. or department head of thor tiniversity or college on official letterhead. contim�ing their status. Postdoctoral fellowsor physicians in training do not qualify for the student registration rate.

�AACR members with paid-up subscriptions to an AACR journal and registrants who pay the nonmember fee receive the Proret’diitgs automatically. If these members or nonmembers

check this box attd � the fee. they will receive an additional copy of the Proeec’thngs.

“Optional paynieni for registrants outside of the U.S. and Canada only. Registrants paying this surcharge will receive meeting publications via airmail--printed matter before the annualmeeting. Fhis service not available alter March 1

AA(’R tsscttibers in good standing will receive copies of the Program and Procc-edings prior to the meeting. Nonmember and student registrants who meet the March 1 deadline willalso receive the Program and (if they have purchased it) the Proeeo/iitg.c prior to the meeting. Nonmembers and students who do not meet the deadline must pick Up publications at theitteeti tig site.

REFUND POLICYRefunds on registratioti fees will be gratited ott written request received in the AACR Office by Aprtl 17. 1996. Requests received after this date will not he honored. Receipts and badges)if (icy have been mailed) must he returned to the AACR Office with the refund request. A cancellation fee of $35 will be deducted from all refunds to cover administrative costs.

�a ASS

xc #{176}c’,�. ‘� -�. �1?�� AMERICAN ASSOCIATION FOR CANCER RESEARCH

kCER 5�

1996 GERTRUDE ELION CANCER RESEARCH AWARD

Supported by an Educational Grant from

Glaxo Welicome Oncology

#{149} This Award was established in honor of Nobel Laureate Dr. Gertrude Elion,

Scientist Emeritus at Glaxo Wellcome Co. and Past President and Honorary

Member of the AACR.

#{149} The Gertrude Elion Cancer Research Award is a one-year, $30,000 grant for

a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or

translational research in cancer etiology, diagnosis, treatment, or prevention

at the level of non-tenured Assistant Professor.

#{149} The AACR will reimburse the Awardee for travel to the 1996 Annual

Meeting in Washington, D.C., where Dr. Elion will personally present this

Award.

Eligibility

Candidates must have completed postdoctoral studies or clinical fellowships not later than July

1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty inacademia, government employees, and employees of private industry are not eligible for thisaward. A Candidate need not be a member of the AACR at the time of application, but mustbe nominated by a Member of the AACR. Associate Members may not be nominators.

Selection Process

Applications are evaluated by a Committee consisting of AACR Members who are experts inbasic, clinical, and translational cancer research. Complete applications must be submitted by

February 15, 1996, to be considered for the I 996 Award.

For Further Information/Application Forms

AMERICAN ASSOCIATION FOR CANCER RESEARCHPublic Ledger Building, Suite 816

1 50 South Independence Mall WestPhiladelphia, PA 19106-3483

Telephone: (215) 440-9300

FAX: (215) 440-9313

e-mail: aacr@aol.com

ATTN. : Jenny Anne Horst-Martz

.

HOTEL RESERVATIONS. .

187TH ANNUAL MEETING

��‘5 ASs0�,

� -�.,

APRIL 20-24, 1996 - � American Association for

WASHINGTON, D.C. ‘ . Ii.v(.ER%5s�”

Cancer Research

CALL FOR RESERVATIONS EARLY!DEADLINE - MARCH 21, 1996

General Information

Please read this page heI�re calling the Washington

Convention atid Visitors Association (WCVA) Housing

Service.

Deposits

A S I 25.00 per room deposit is required, payable by credit card

Ol� check.

#{149}Credit card - Your credit card will he charged

imlilediately. Most lilajor credit cards are accepted. Your

R)Ol11 conlirlilation will he sent U�Ofl acceptance of your

credit card charge.

#{149}Check - An invoice for the S I 25.00 per room deposit will

he niailed to you. Payment niust he received within IS

days of the invoice date or your reservation will he

cancelled. Do not send payl1�ent without an invoice stub.

Your rooni conlirmation will he sent upon receipt of check.

Changes

#{149}Prior to March 21. 1996. all changes should he made with

the WCVA Housing Service. Al’ter March 21, chaliges

should be made with the hotel.

Cancellations/Refunds

#{149}Cancellations made prior to March 2 1 . I 996 should he

lilade with the WCVA Housing Service and will he

refunded iii full. The WCVA Housing Service will issue

the refund.

S Cancellations llutde after March 2 1 , and prior to 72 hours

of’ arrival should he made with the hotel. A $lO.O() service

(‘cc will he deducted l’roni your deposit. The hotel will

issue the refund.

Instructions

Call the WCVA Housing Service, Monday through Friday,

from 9:00 am. to 5:00 p.m. Eastern Time. The hotels will not

accept reservations directly.

#{149}Conferees in the United States and Canada -- call

1-800-535-3336.

#{149}Conferees in the Washington. D.C.. area and International

Conferees -- call 202-842-2930.

#{149}International Conferees ONLY -- FAX 202-289-8079.

Tell the WCVA Housing Service operator you are calling for

the AACR Annual Meeting hotel reservations. Please have

the following information ready:

I . Hotel preference ( I st. 2nd. and 3rd choices)

2. Arrival and departure dates and times

(indicate arrival after 6:0() p.m.)

3. Number of rooms required

4. Accol11n�odations desired

Single

Double ( I bed, 2 people)

Twin (2 beds. 2 people)

Triple

Quad (2 double beds, 4 people)

Suite

5. Number of people in party

6. Credit card name. account number, name as it

appears on card. and expiration date

7. Nanies 01 all occupants ol rooni(s)

8. Address

9. Daytime telephone number with area code

10. FAX number with area code

I I . Special requests (disability. smoking/nonsmoking.

king-size bed. etc.)

Inquiries

Washington Convention & Visitors Association

Housing Service

1212 New York Avenue. NW.

Washington. D.C. 20005-3992

HOTELS IN WASHINGTON, D.C.RESERVING ROOMS FOR AACR REGISTRANTS

MAPNUMBER HOTEL NAME SINGLE DOUBLE

1 Grand Hyatt Washington* $ 1 68 $ I 88

2 Renaissance Washington, D.C. Hotel*Main Hotel $154 $174Renaissance Club - Tower $ 1 74 $ I 94

3 The Bellevue Hotel $ 109 $124

4 The Capital Hilton $ I 79 $199

5 The Comfort Inn $99 $99

6 Days Inn Downtown $99 $99

7 The Henley Park Hotel $157 $177

8 Holiday Inn Central $ 105 $105

9 Holiday Inn Franklin Square $ I 05 $105

10 Holiday Inn on the Hill $ 1 29 $ I 39

I I Hotel Washington $ 150 $ I 50

12 Marriott at Metro Center $ 159 $ I 59

13 Phoenix Park $150 $170

14 Stouffer Renaissance Mayflower Hotel $ 169 $ I 99

15 The Washington Court $ 160 $160

16 The Washington Vista $ 155 $ I 65

*Co..Headquarters

ALL RATES ARE SUBJECT TO A 13% DISTRICT OF COLUMBIA TAX AND A $1.50OCCUPANCY TAX PER ROOM PER NIGHT.

MAP OF WASHINGTON, D.C. SHOWING HOTELSRESERVING ROOMS FOR AACR REGISTRANTS

w.>-_�c� !� �!

o.� Et o

a) .� 0� �C � �

�

.�ta, �

�.= �.- U) ��.1 � <

�±_-� �

>. �

�: �� �.� �

Q, �-c �(,, .- 0 � �� 00 � � � � -

= �,, c� � �a3 C � .� �

:� 0 ‘ .� w

.� ‘E �i E = Co

�=cn_� �

<thc.iciLLi U

U,

4z

II JAI LIdv, �

�inr�i#{149}�

4

I

f1)

0

0

0

.�

0

0

0

‘I

Id0

.�

E

CANCER CLINICAL

TRIALS

The National Cancer Institute

The National Cancer Institute is seeking

referral of patients with advanced cancer of

the colon, stomach, esophagus, breast,

lung, or bladder that is no longer responsive

to standard therapy. Patients will be evalu-

ated at the Clinical Center of the National

Institutes of Health and, if found to be

eligible, will be offered participation in an

investigational trial of a genetically engi-

neered immunotoxin.

For more information, please call:

(301)4969458

AMERICAN BOARD OFINTERNAL MEDICINE

1996 Certification Examination in Hematology

Registration Period:

January 1. 1996 - April 1. 1996

Exalnination Date:

November 20, 1996

For �i�ore inforl1�ation and applicatioll forl1�s,

please contact:

Registration Section

American Board of Internal Medicine

3624 Market Street

Philadelphia. PA 19104

Telephone: (800) 441-2246 #{149}(215) 243-1500

Fax: (215) 382-5515

AMERICAN ASSOCIATION FOR CANCER RESEARCH

1996 RESEARCH FELLOWSHIPS

For Young Scientists at the Postdoctoral

on Clinical Fellow Level

The purpose of the AACR’s 1996 Research Fellowship in

Clinical/ Translational Research, sponsored by Amgen, Inc. and

its 1996 Research Fellowship in Basic Research is to foster

meritorious clinical, translational, on basic research in the U.S.

or Canada by a young scientist currently at the postdoctoral or

clinical research fellow level. Candidates must have been a

fellow for at least two years but no more than five years prior

to the beginning of the award year (July 1996). Academic

faculty holding the rank of assistant professor or higher,

graduate on medical students, government employees, and

employees of private industry are not eligible.

Terms: Both Fellowships provide a one-year grant of $30,000.

Candidates must be nominated by a member of the AACR and

submit a detailed application.

Deadline: February 15, 1996

For application information contact:

Jenny Anne Honst-Mantz

American Association for Cancer Research

Public Ledger Building, Suite 816

150 South Independence Mall West

Philadelphia, PA 19106-3483

(215) 440-9300; FAX (215) 440-9313

Email: jahmaacn@aol.com

AMERICAN ASSOCIATION FOR

CANCER RESEARCH

The American Association for Cancer Research(AACR) is a professional society of over 10,600

scientists and physicians involved in all aspects of

basic, clinical, and translational cancer research.

Members of the AACR enjoy

. subscriptions to Cancer Research, Cell Growth &Differentiation (CG&D), Cancer Epidemiology,

Biomarkers & Prevention, and Clinical Cancer

Research at reduced member rates

. reduced registration rates at the AACR Annual

Meeting, Special Conferences, and International

Meetings

. Employment Register, Directory of Members,

public education activities, and many other

benefits

Special programs to provide enhanced career devel-

opment opportunities for minority scientists include

. Session on Career Development at Annual

Meeting. Mentorship Program. Travel Awards to Scientific Meetings

American Association for Cancer ResearchPublic Ledger Building, Suite 816

150 S. Independence Mall West

Philadelphia, PA 19106-3483

Telephone: (215) 440-9300

FAX: (215) 440-9313 I E-Mail: aacr@aol.com

ASSo�

0 ‘9#{176}7 �

1kCER 1�

AMERICAN ASSOCIATION FOR CANCER RESEARCHSCIENTIFIC CONFERENCES

JANUARY 17-20, 1996Cancer and the Cell Cycle

Joint Meeting with the Swiss Institute forExperimental Cancer Research

Chairpersons: Edward E. Harlow, Charlestown,MA; Viesturs Simanis, Lausanne, Switzerland

Centre Hospitalier Universitaire Vaudois,Lausanne, Switzerland

FEBRUARY 19-25, 1996Cancer Susceptibility Genes and

Molecular CarcinogenesisChairpersons: Curtis C. Harris, Bethesda, MD;

Allan Balmain, Glasgow, Scotland; KennethOlden, Research Triangle Park, NC

Keystone Resort, Keystone, CO

MARCH 1-5, 1996Proteases and Protease Inhibitors

Chairpersons: Lynn M. Matrisian, Nashville, TN;Bonnie F. Sloane, Detroit, Ml

Marriott’s Bay Point Resort, Panama CityBeach, FL

APRIL 20-24, 199687th Annual Meeting

Chairperson: Lorraine J. Gudas, New York, NYWashington D.C. Convention Center,

Washington, D.C.Abstract Deadline: December 1, 1995

JUNE 8-12, 1996Inducible Genomic Responses

Chairpersons: William T. Beck, Memphis, TN;John A. Hickman, Manchester, England;Richard I. Morimoto, Evanston, IL

Skamania Lodge, Stevenson (Columbia RiverGorge), WA

OCTOBER 2-6, 1996Novel Approaches in Blood and

Marrow TransplantationSecond Annual Meeting of the American Society

for Blood and Marrow TransplantationChairpersons: 0. Michael Colvin, Durham, NC;

Bruce R. Blazar, Minneapolis, MNHotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996Carcinogenesis from Environmental

Pollution: Assessment of Human Risksand Strategies for Prevention

Joint Meeting with International Agency forResearch on Cancer

Chairpersons: Frederica Perera, New York, NY;Paul Kleihues, Lyon, France

Hotel Gell#{233}rt,Budapest, Hungary

OCTOBER 19-23, 1996Programmed Cell Death

Chairperson: Stanley J. Korsmeyer, St. Louis, MOThe Sagamore, Bolton Landing (Lake George), NY

JANUARY 17-21, 1997Disrupted Transcription Factors in Cancer

Chairpersons: Peter K. Vogt, La Jolla, CA; FrankJ. Rauscher Ill, Philadelphia, PA

Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997Growth Factors and Cancer

Joint Meeting with Lorne Cancer CongressChairpersons: Antony Burgess, Parkville, Victoria,

Australia; Robert S. Coffey, Nashville, TN;Ashley R. Dunn, Parkville, Victoria, Australia;Raymond L. White, Salt Lake City, UT

Erskine House, Lame, Victoria, Australia

AACR members will receive brochures on theabove special conferences as soon as they areavailable. Nonmembers should call or write:

American Association for Cancer ResearchPublic Ledger Building, Suite 816150 South Independence Mall WestPhiladelphia, PA 19106-348321 5-440-9300 #{149}21 5-440-931 3 (FAX)E-Mail: aacr@aol.com

1kCER %5�

1996 ANNUAL MEETING

TITLES OF MAJOR SESSIONS(Confirmed Chairpersons in Parentheses)

AMERICAN ASSOCIATION FOR CANCER RESEARCH

April 20-24, 1996

Washington, D.C.

Convention Center

The Latest

Developments in

All Areas of

Cancer Research

Program Chairperson:

Lorraine J. Gudas

Major Presentations

the Foremost Scient

in the Field

Minisymposia, Postt

Discussion Sessions,

and Poster Sessions

Proffered Papers

Abstract Deadline:December 1, 1995

For More Information:

AACR Office

Public Ledger Building

Suite 816

150 5. Independence MallPhiladelphia, PA 19106-34)

� 215-440-9300

Fax 215-440-9313

Email aacr@aol.com

An Essential

Multidisciplinaiy

Program for

Laboratory and

Clinical Cancer

Researchers

Special Plenary Session

Twenty-fifth Anniversary of the National Cancer

Act: Progress and Promise (Joseph R. Bertino)

Symposia

Apoptosis: Manipulating Programmed Cell Death in

Cancer (David E. Fisher)

Matrix Metalloproteinases and Their Inhibitors

(Lynn M. Matrisian)

Cell Cycle: Targets for Therapy (Stephen H. Friend)

Endogenous DNA Damage: Detection and Biological

Significance (John M. Essigmann)

Cell Signaling (Channing Der and Deborah Morrison)

Recent Developments in Gene Therapy

(Drew M. Pardoll)

Cancer Chemoprevention in Humans

(Thomas W. Kensler)

Genetic Predisposition to Cancer (Mark H. Skolnick)

Cell Responses to DNA Damaging Agents

(Nathan A. Berger)

Drug Resistance: Transcriptional and Translational

Mechanisms (Kathleen W. Scotto)

Monoclonal Antibodies: Clinical Mechanisms and

Effectiveness (Ellen S. Vitetta)

Targeting Growth Factor Receptors for Therapy

(John Mendelsohn)

Melanoma as a Clinical Model (Alan N. Houghton)

Thymidylate Synthetase and Its Inhibitors

Nutrition and Cancer (Walter C. Willett)

Aberrant Transcription Factors and Malignancy

(Lorraine J. Gudas)

Steroid Hormones: Breast and Prostate Cancer

(Myles A. Brown)

Viral Mechanisms of Carcinogenesis

(Harald zur Hausen)

Tumor Suppressor Genes (Bert Vogelstein)

Ovarian Cancer: From the Laboratory to the Clinic

(Robert F. Ozols)

Drug Metabolizing Enzymes in Cancer Prevention and

Therapy (Cecil B. Pickett)

Cell Adhesion Molecules and the Cytoskeleton

(Jun-Lin Guan and Rudolph L. Juliano)

Tumor Angiogenesis (Judah Folkman and Mark A.

Goldberg)

Neuroblastoma: Recent Advances in Diagnosis and

Treatment (Garrett M. Brodeur)

Telomerase, Cell Senescence, and Cancer

(Calvin B. Harley)

Pre-Meeting Methods Workshops

Quantitative Biology and Pharmacodynamics

(Robert C. Jackson)

Animal Models: Transgenic and Knockout Mice in

Cancer Investigations (Terry A. Van Dyke)

Controversy Sessions

Does Regional Chemotherapy Work?

(David S. Alberts)

Is Beta-Carotene Useful in Cancer Prevention?

(Waun Ki Hong)

In Studies of Drug Resistance, Have Preclinical

Models Provided Accurate Predictions for

Clinicians? (Bruce A. Chabner)

Is p53/Rb Important for Therapeutic Outcome?

(William F. Benedict)

Should Genetic Testing Be Done on Patients to

Assess Cancer Risk? (Judy E. Garber)

Meet-The-Expert Sunrise Sessions

Quantitative PCR As a Tool to Detect Minimal

Residual Disease in Lymphoma and Leukemia

(John Gribben)

Inhibition of Tobacco-induced Carcinogenesis

(Stephen S. Hecht)

Cell Cycle (Peggy J. Farnham)

Drugs Which Interact with Microtubules: An Update

(Eric K. Rowinsky)

Culturing Normal and Neoplastically Transformed

Human Epithelial Cells (Martha R. Stampfer)

Mammary Carcinogenesis (Daniel Medina)

Radiation Sensitization (Theodore S. Lawrence)

NMR As a Prognosticator (Jerry D. Glickson)

Antiestrogens (V. Craig Jordan)

DNA Topoisomerases and Their Inhibitors

(Yves G. Pommier)

Estrogens and Breast Cancer (Lovell A. Jones)

Tumor Physiology (Rakesh K. Jam)

Protein Kinase C in Cell Transformation

(Susan Jaken)

Environmental Carcinogens: Their Impact in Cancer

(John A. McLachlan)

Lung Cancer: A Primer

Chromosomal Deletions and Cancer: Recent

Advances in Mapping Techniques

(Funmi I. Olopade)

Tumor Vaccines (Jeffrey Schlom)

Challenges in Bone Marrow Transplantation

(William S. Dalton)

Immunologic Features of AIDS Pathogenesis

(Jay A. Levy)

Natural Killer Cells (Ronald B. Herberman)

Interferons and Cancer (Ernest C. Borden)

Transcription Factors As Therapeutic Targets

(Richard A. Heyman)

Chemokines and Leukocyte-specific Chemotactic and

Activating Factors (Barrett J. Rollins)

Bcl and Cell Death (Stanley J. Korsmeyer)

Prodrugs (Peter D. Senter)

Specific Immunotherapy of Melanoma

(Philip Livingston)

Diet and Tumorigenesis (Diane F. Birt)

Childhood Leukemias: The Latest in Treatment

(Steven E. Sallan)